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Introduction 
Protein-protein, protein-peptide, and peptide-peptide interactions are intrinsic 
to virtually most of cellular processes. Any listing of major research topics in 
biology — i.e., DNA replication, transcription, translation, splicing, secretion, 
cell cycle control, signal transduction, and intermediary metabolism — is also 
a listing of processes in which protein complexes have been implicated as 
essential components. As a consequence, the analysis of interactions between 
these complexes is no longer the exclusive domain of developmental biologists 
or molecular biologists; in fact chemical biologists and biophysicists have 
gotten by necessity into the act. Therefore, protein-protein interactions play an 
essential role for any process in a living cell in any different competence 
scientific field. Amplifying knowledge about these interactions could possibly 
allow to better understand protein-based disease conditions and could provide 
the basis for new therapeutic approaches. 
The main purpose of this study performed during my PhD research project was 
to apply both classical and recent methods to identify and characterize antigen-
antibody interactions, and to assess the strength of these interactions in the 
particular case study of Multiple Sclerosis. 
Antigen-Antibody interaction 
The antigen (Ag) is usually a protein molecule that often protrudes from the 
surface of a cell inducing an immune response and producing specific 
antibodies. The modern definition encompasses all substances that can be 
recognized by the adaptive immune system. In a strict sense, antigens are those 
substances eliciting a response from the immune system, whereas antigens are 
all those defined molecules binding to specific antibodies. 
Cells present antigens to the immune system via Major Histocompatibility 
Complex (MHC). Depending on the antigen presented and the type of 
histocompatibility molecule, several types of immune cells can be activated. 
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Antibodies (Abs), also known as immunoglobulins, are used by the immune 
system to identify and neutralize foreign objects, such as bacteria and viruses. 
Antibodies can bind to different targets, allowing the immune system to 
recognize an equally wide diversity of antigens.  
The specific association of antigens and antibodies is strongly dependent on 
hydrogen bonds, hydrophobic interactions, electrostatic, and Van der Waals 
forces. All antigen-antibody binding is reversible, and follows the basic 
thermodynamic principles of any reversible bimolecular interaction. 
While B lymphocytes become stimulated, by those macromolecules (i.e. 
protein antigens) triggering a humoral response, the specific affinity of an 
antibody is not for the entire macromolecular antigen but for a particular 
portion or site of the protein antigen, which could be mimicked by a peptide. 
Small dimensions molecules cannot induce an adaptive immune response by 
themselves. These small molecules can be recognized by antibodies only after 
their conjugation to some macromolecules. In this case the small molecule is 
termed hapten, while the macromolecule is the carrier. Therefore the complex 
hapten-carrier is able to work as an immunogen. Moreover, relative low mass 
peptides are usually not immunogenic and need to be coupled to carriers to 
induce or augment an anti-peptide humoral immune response. This is the case 
for human little gastrin where conventional gastrin/carrier protein conjugates 
prepared via classical crosslinking reactions generally lead to strong anti-
gastrin responses in terms of antisera titers.1 
An antibody binds only a determinant or an epitope region of a macromolecule, 
which can also contain multiple determinants. Globular proteins generally do 
not contain identical repeated epitopes. While, in the case of polysaccharides 
and nucleic acids numerous identical determinants to regular intervals can be 
found again. 
                                                     
1  Moroder, L.; Kocher, K.; Papini, A.M.; Dufresne,M. Chemistry of peptides and 
proteins, 1993, 783-791. 
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The epitopes composed by linear (closed) amino acid sequences are termed 
linear epitopes. Usually, the binding site of an antibody can lodge an 
antigenic epitope of approximately 6 amino acids. Linear epitopes can be 
accessible to antibodies if they are exposed on the external surface of the 
antigen or in a conformationally extended region in the folded native protein. 
Differently, in conformational epitopes, the antibody interacts with amino 
acids not sequentially linked but spatially close one to each other, because of 
the protein folding. The variety of possible binding sites is huge with each 
potential binding site having its own structural properties derived by covalent 
bonds, ionic bonds, hydrophilic, and hydrophobic interactions characteristics 
of amino acid side-chains (Figure 1). 
 
Figure 1. MHC-I bound epitope is scanned by T-cell receptor. 
T cell recognition of glycopeptides may be important in the immune defense 
against microorganisms due to the fact that many microbial antigens are 
glycosylated. Evidences about T cell recognition of protein glycans may be 
crucial also for T cell responses to autoantigens in the course of autoimmune 
diseases.2 Therefore, glycopeptides with simple sugars can be suitable tools to 
investigate the antigen fine specificity of glycoprotein-specific T cells. 
                                                     
2 Bäcklund, J., Carlsen, S., Höger, T., Holm, B., Fugger, L., Kihlberg, J., Burkhardt, H. 
& Holmdahl, R. Proc. Natl. Acad. Sci. USA  2002, 99, 9960–9965. 
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Therefore, co- or post-translational modifications, e.g. glycosylation, as well 
as proteolysis can alter the native protein covalent structure generating new 
epitopes. These modified regions are termed neo-antigenic epitopes and can be 
recognized by different specific antibodies. 
Molecular mechanisms of autoimmune diseases 
Autoimmune diseases affect at least 5% of the whole population and have a 
high social impact, because patients have a long expectation of life during 
which they are subordinated to the follow up of the disease by means of very 
invasive techniques, e.g. Magnetic Resonance Imaging (MRI), that are not 
suitable for a routine use.  
In order to investigate the molecular mechanisms of autoimmune diseases, it is 
necessary to introduce the immune system, which is based on the ability to 
distinguish foreign molecules from self molecules. After the introduction of an 
unknown agent that is potentially pathogenic (antigen), the organism can reply 
to the attack by two different reactions of the immune system: the antibody 
(Ab) or humoral response and the cell-mediated immune response. 
• Humoral responses involve antibodies that are produced by B-
lymphocytes and are able to bind specifically to the foreign antigen. B-
lymphocytes create an antigen/antibody complex to neutralize and kill the 
foreign, dangerous molecule. B-cells are programmed to produce a single 
antibody class, especially receptors for proteins or peptide fragments that 
present a high affinity (epitopes). 
• Cell-mediated immune responses involve the production of specialized 
cells that react with foreign antigens on the surface of other host cells. T-
lymphocytes, employed in cell-mediated responses, stimulate B-lymphocytes 
and fight against foreign substances by using a composite mechanism. T-
lymphocytes kill infected cells and expose fragments on the membrane surface. 
The Antigen Presenting Cell (APC) exposes peptide fragments, derived from 
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hydrolysis of all the proteins being into the cell, by a special class of cell-
surface glycoproteins, e.g. the MHC molecules. 
Foreign molecules can substitute self peptides and cause the reaction of the 
immune system. T-cells use a specific T-cell Receptor and induce the 
formation of the MHC/peptide antigen complex. This trimolecular complex 
induces immune responses. 
 
Figure 2. Mechanism of the immune response. 
Autoimmune diseases are due to a "mistake of evaluation" of the immune 
system, which no more recognizes self-antigens.3 The immune system can 
occasionally attack self-antigens triggering an autoimmune response, with 
damages to the tissues on which these antigens are expressed. Autoimmune 
disorders are up to now considered as triggered by T lymphocytes further 
inducing an autoantibody response.  
In some autoimmune disorders a pathologic immune response is localised to 
specific antigens confined to a particular organ system. Alternatively, systemic 
autoimmune diseases are characterized by an immune response to ubiquitous 
                                                     
3 N. Rose, I. Mackay, The Autoimmune Diseases, 2006, Elsevier Academic Press, 4th 
edition. 
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intracellular antigens in which the relationship between immune specificity 
and disease manifestations may not be obvious. 
It is now accepted that autoimmune diseases have a multifactorial origin 
including genetic predisposition, endogenous, and exogenous elements. Many 
infectious bacteria and viruses contain surface carbohydrates with a very 
similar molecular structure and/or conformation to mammalian surface 
glycoproteins and glycolipids. Molecular mimicry is the process by which 
viruses or bacteria activate an immune response because of a cross-reaction 
with self-antigens (Figure 3).4 Moreover, such homology should involve a 
self-determinant displaying an important biological activity so that the immune 
attack injures tissues and cause a disease. As an example, in Guillain Barré 
syndrome (GBS), which is considered a prototype of post-infectious 
autoimmune disease, molecular mimicry has been considered responsible of 
triggering the disease. Clinically, GBS is characterized by an acute ascending 
flaccid paralysis that is often generated by a preceding viral or bacterial 
infection. The most commonly identified triggering agents are pathogens 
having carbohydrate sequences (considered the antigens) in common with 
peripheral nervous tissue. 
 
Figure 3. Molecular mimicry. 
In other autoimmune diseases in which the antigens have not yet been 
characterised, possibly not only carbohydrates can modify by a covalent bond 
                                                     
4 Oldstone, M. B. A. Cell 1987, 50, 819-820. 
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a self-protein antigen, which will become a non-self one triggering an 
abnormal antibody response. 5  Therefore, aberrant glycosylation of self-
antigens (proteins) can be responsible of influencing the level of epitope 
production, and the generation of neoepitopes, leading to autoimmune 
responses. 
It is evident that different hypotheses have been proposed to explain 
autoimmune processes to dissect the intricate pathogeneses of such diseases in 
the natural complexity of the biochemical mechanisms.  
Antibodies as biomarkers of autoimmune diseases 
A biomarker is an anatomical, physiological, and/or biochemical parameter, 
which should be easily determined and used as indicator of normal 
physiological or pathogenic processes. Molecules present in tissues and 
biological fluids can be identified as biomarkers and used to set up 
diagnostic/prognostic tools. Moreover, biomarkers can be used also for 
monitoring the efficacy of a therapeutic treatment. Sera from patients suffering 
from autoimmune disorders often contain multiple types of autoantibodies. 
Some autoantibodies can be exclusive of a disease and used as biomarkers. In 
particular, if they fluctuate with disease exacerbations or remissions, 
autoantibody detection is extremely valuable in the follow up of patients. 
Consequently, the antibodies present in patients’ serum can be used as disease 
biomarkers. 6 , 7  Therefore, evaluation of antibodies as disease specific 
biomarkers is extremely important not only for diagnosis, follow-up, and 
prevention of autoimmune diseases, but also for “theragnostics”, i.e. 
evaluation of efficacy of specific therapeutic treatments.8,9 
                                                     
5 S. Mouritsen, M. Meldal, I. Christiansen-Brams, H. Elsner, O. Werdelin, Eur. J. 
Immunol., 1994, 24, 1066-1072. 
6 D. Leslie, P. Lipsky, A. L. Notkins, J Clin Invest 2001, 108, 1417-1422. 
7  Alcaro, M.C.; Lolli, F.; Migliorini, P.; Chelli, M.; Rovero, P.; Papini, A.M. 
Chemistry Today 2007, 25 (5), 14-16. 
8 P. Roland, P.; Atkinson, J.A.; Lesko, L.J. Clin. Pharm. Ther. 2003, 73, 284-291. 
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Native proteins formulate antigens and have been exploited to raise antibodies 
for different purposes. This characteristics was translated in their use to 
identify autoantibodies that was traditionally achieved using directly damaged 
patients’ tissues containing triggering agents in different immunoassays. 
Biological fluids containing autoantibodies have replaced the use of damaged 
tissues as a non-invasive alternative. Unfortunately, in autoimmune diseases 
only very low specific antibodies were demonstrated to be detected in serum, 
possibly because proteins used in the assays were not reproducing the real 
autoantigen. Moreover, an entire protein should contain more than one epitope 
specific for different autoantibodies. Yet, growing evidences indicate that post-
translational modifications, either native or aberrant, may play a fundamental 
role for specific autoantibody recognition in autoimmune diseases.10 These 
observations account, at least in part, for the limited success got in the 
discovery of biomarkers for autoimmune diseases using proteomic analysis 
and/or protein microarrays.  
From Radio-Immuno Assay to Enzyme-Linked 
Immunosorbent Assay 
Over the past years, autoimmunity diagnosis has gone through a very dynamic 
period, associated with the introduction of new tests deriving from the 
identification of various new families of autoantibodies and the demonstration 
of their usefulness in clinic. A better knowledge of autoantigen molecules has 
been associated with the very rapid growth of molecular biology technologies. 
In the field of autoimmune diseases, a number of autoantibody detection 
techniques have been developed. Radio-Immuno Assay (RIA) has been 
traditionally used in autoantibody detection and it is based on labelled targets 
providing a radioactive signal. In fist versions of RIA, a radioactive-labelled 
                                                                                                                                
9 Baker, M.; Nature Biotech. 2005, 23, 297-304. 
10 Doyle, H.A.; Mamula, M.J. Trends Immunol. 2001, 22, 443-449. 
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substance, or isotopes of the substance, was mixed with antibodies and 
inserted in a sample containing patient's tissue. The same non-radioactive 
substance in these tissues took the place of the isotope in the antibodies, thus 
leaving the radioactive substance free, generating a signal. Up to now, 
autoantibodies detection in assays is usually performed using recombinant 
native protein antigens as non-invasive protocols. Moreover, RIA also requires 
special radioactivity instrumentation and precautions. Therefore, today RIA 
was largely supplanted by the Enzyme-Linked Immunosorbent Assay (ELISA) 
when possible, because in ELISA the antigen-antibody reaction is measured 
using a colorimetric signal instead of a radioactive signal. 
Even more recently, the application of proteomic technologies for the 
diagnosis of autoimmune diseases has opened new diagnostic scenarios, which 
could revolutionize diagnostic procedures in future suggesting some 
interesting opportunities. 
From peptide-epitope discovery to peptide-based 
immunoassays 
In autoimmune diseases, characterization of autoantibodies by protein antigens 
isolated from biological material or reproduced by recombinant technologies 
has sometimes turned out as an unrealistic approach. In fact the big limit in 
using such material is a mistake in epitope recognition because of mutations 
and/or unfolded sequences, or lack of post-translational modifications. 
The most logical alternative could be the use of peptides derived from native 
protein sequences and reproducing specific epitopes including the hapten. In 
some instances, antibody recognition by peptides could be even more effective 
and specific than by native proteins. 
Peptides are particularly useful when the epitope sequence has been 
discovered inside the total protein. In fact, native protein antigens (particularly 
if underexpressed) can be difficult to be fully sequenced or cannot often be 
successfully reproduced using recombinant techniques. In any case protein 
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folding can be also a difficult task. Moreover, proteins may be difficult to 
isolate with correct co- or post-translational modifications. On the contrary, 
epitope discovery by peptides as synthetic antigens requires only identifying 
an amino acid sequence limited in length. Exposition of the epitope is a 
challenge to optimise antibody recognition. Moreover, peptide antigens can 
display enhanced recognition specificity eliminating or minimizing potential 
cross-reactivity between structurally homologous protein epitopes. 
Peptides have several advantages: they are relatively easy to produce and may 
retain chemical stability over time. Moreover, reproduction of co- or post-
translational modifications in peptides, synthetically speaking, is a quite easy 
task compared to recombinant techniques.11 Therefore theoretical ability to 
understand the immune response with defined peptide epitopes can have 
important advantages. Nowadays these hypotheses are confirmed by a limited 
number of peptide-based assays widely expanding for characterization of 
antibodies in different infectious diseases, i.e. Scheriacoli, Salmonella, 12 
Chlamydia trachomatis, 13 etc.  
In the particular case of Reumathoid Arthritis (RA), several aberrant 
modifications of proteins (such as Arg deimination leading to citrulline 
formation and/or methylation) have been associated with its pathogenesis and 
lead to the development of different synthetic modified antigens used in simple 
ELISA.10 A key step in setting up the commercially available ELISA for RA 
was represented by identification of deiminated sequences of filaggrin that are 
recognized in a high percentage of RA sera.14,15 Sensitivity of the assay was 
                                                     
11 Papini, A.M. “Peptide-based Immunoassays for Biomarkers Detection: a Challenge 
for Translational Research” Zervas Award Lecture 30th European Peptide Symposium, 
August 31-September 5 2008, Helsinki, Finland. 
12 Kulaginaa, N. V.; Shaffera, K.M.; Anderson, G.P.; Liglera, F.S.; Taitt, C. R. Anal. 
Chim. Acta, 2006, 575, 9-15. 
13 Morré, S.; Munk, C.; Persson, K.; Krüger-Kjaer, S.; Van Dijk, R.; Meijer, C.; Van 
den Brule, A. J Clin Microbiol. 2002, 40(2), 584–587. 
14 Sebbag, M.; Simon, M.; Vincent, C.; Masson-Bessiere, C.; Girbal, E.; Durieux, J.J.; 
Serre, G.; J. Clin. Invest. 1995, 95, 2672-2679 
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increased modifying the peptide structure to optimally expose the citrulline 
moiety. In fact a cyclic citrullinated peptide allows detection of antibodies in 
up to 70% RA patients.16 This ELISA is now considered a gold standard for 
RA diagnosis and follow up.  
Epitope discovery by a “Chemical Reverse Approach” in 
autoimmune diseases 
In order to develop optimised synthetic peptides as antigenic probes for fishing 
out autoantibodies from biological fluids as biomarkers, an innovative 
“Chemical Reverse Approach” has been developed for the fist time in the 
Laboratory of Peptide and Protein Chemistry and Biology (PeptLab). This 
approach was defined “Reverse” because the screening of the synthetic 
antigenic probe is guided by autoantibodies circulating in autoimmune disease 
patients’ blood. “Chemical” because autoantibody recognition drives selection 
and optimisation of the “chemical” structure from defined peptide libraries.17 
Thus, autoantibodies circulating in patients’ biological fluids allow the 
selection of synthetic post-translationally modified peptides mimicking new 
epitopes in antigens. Peptide epitopes identified by this approach, if selectively 
and specifically recognizing autoantibodies in a statistical significant number 
of patients, can be used as antigenic probes in immunoenzymatic assays to 
detect disease biomarkers in an efficient synthetic way. 
The screening of focused libraries of unique modified peptide molecules is a 
valuable strategy to obtain optimised peptide antigens containing the minimal 
epitope with the correct modification to detect at the best autoantibodies 
                                                                                                                                
15 Serre, G. Joint Bone Spine 2001, 68, 103-105 
16 Schellekens, G.A.;. de Jong, B.A.; van den Hoogen, F.H.; van de Putte, L.B.; van 
Venrooij, W.J. J. Clin. Invest. 1998, 101, 273-281 
17 Papini, A.M. “A Chemical Reverse Approach to Modified Peptides as Synthetic 
Antigenic Probes to detect autoantibodies as Biomarkers of Multiple Sclerosis”. 1st 
Dimitrios Theodoropoulos Memorial Lecture Award. 6th Hellenic Forum on Bioactive 
Peptides, May 18, 2008, Patras, Greece. 
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specific of the autoimmune disease under investigation. 18   As a proof-of-
concept this approach has been successfully applied for the identification of 
autoantibodies as biomarkers of an autoimmune mediated form of Multiple 
Sclerosis, the most difficult disease because protein antigens are localized in 
the central nervous system. 
Multiple Sclerosis and the glucosylated peptide 
CSF114(Glc) as mimetic of  protein autoantigens 
Multiple Sclerosis (MS) is an autoimmune, chronic, inflammatory, 
demyelinating disease of the central nervous system (CNS), which represents a 
group of very heterogeneous disorders. Distinctive neuropathological features 
are present in the disorder suggesting different pathophysiological mechanisms 
leading to the formation of myelin lesions.19,20 Several data suggest that the 
disease pathogenesis is linked to an autoimmune mechanism against the 
prominent CNS myelin antigens,21 possibly triggered by a viral or bacterial 
infection. The target antigens are not definitively defined because of their 
difficult localization. Multiple Sclerosis lesions are characterized by large 
sharply, demarcated areas of demyelination, with macrophage infiltration and 
accumulation of T lymphocytes. Different self-proteins of myelin have been 
investigated as potent targets for T or B cells in Multiple Sclerosis, e.g. Myelin 
Oligodentrocyte Glycoprotein (MOG). 
                                                     
18 Lolli, F.; Rovero, P.; Chelli, M.; Papini, A.M. Expert Rev. Neurotherapeutics 2006, 
6 (5), 781-794. 
19 Lucchinetti C, Bruck W, Rodriguez M, Lassmann H. Brain Pathol 1996, 6, 259-274. 
20 Lassmann H: Multiple Sclerosis 1998, 4, 93–98. 
21 Martin, R.; McFarland, H. Crit. Rev. Clin. Lab. Sci. 1995, 32, 121-182. 
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Figure 4. Possible therapeutic targets: (1) depletion or inhibition of T 
cells, (2) depletion or inhibition of plasma cells, (3) interference with 
the molecular mechanisms of T-cell activation, (4) inhibition of 
lymphocyte migration, and (5) inhibition of soluble mediators, such as 
cytokines and chemokines. MHC, major histocompatibility complex; 
TCR, T-cell receptor. 
In particular, in the Laboratory of Peptide & Protein Chemistry & Biology of 
the University of Florence, it was demonstrated that the glucosylated peptide 
[Asn31(Glc)hMOG(30-50)] is able to detect autoantibodies in Multiple 
Sclerosis patients’ sera by ELISA experiments. 22  It was observed that the 
ability of the glucosylated peptide to detect autoantibodies in Multiple 
Sclerosis was linked to characteristics other than conformation and that the 
specific autoantibody binding site on MOG glycopeptide was related to the N-
linked glucosyl moiety.23 
                                                     
22 Mazzucco, S.; Mata, S.; Vergelli, M.; Fioresi, R.; Nardi, E.; Mazzanti, B.; Chelli, M.; 
Lolli, F.; Ginanneschi, M.; Pinto, F.; Massacesi, L.; Papini, A. M. Bioorg. Med. Chem. 
Lett. 1999, 9, 167-172. 
23 Carotenuto, A.; D’Ursi, A.M.; Nardi, E.; Papini, A.M.; Rovero, P. J. Med.Chem, 
2001, 44, 2378-2381. 
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Hence, the recognition properties of the molecule were optimized through the 
design and screening of focused libraries of glycopeptides by a “Chemical 
Reverse Approach”. The family of specific antigenic probes, CSF114(Glc), 
was developed to identify autoantibodies, as biomarkers of Multiple Sclerosis 
correlating with disease activity. The glycopeptides based on CSF114(Glc), a 
structure-based designed glucosylated peptide as first Multiple Sclerosis 
Antigenic Probe (MSAP), 24 , 25 are able to measure accurately high affinity 
autoantibodies in sera of a statistically significant patients’ population.26,27 The 
glycopeptides are characterised by different types of β-turn structures bearing 
as minimal epitope a β-D-glucopyranosyl moiety linked to an Asn residue on 
the tip of the turn possibly reproducing an aberrant N-glucosylation of myelin 
proteins fundamental for autoantibody recognition.22,28 
                                                     
24 Lolli, F.; Mulinacci, B.; Carotenuto, A.; Bonetti, B.; Sabatino, G.; Mazzanti, B.; 
D’Ursi, A. M.; Novellino, E.; Pazzagli, M.; Lovato, L.; Alcaro, M. C.; Peroni, E.; 
Pozo-Carrero, M. C.; Nuti, F.; Battistini, L.; Borsellino, G.; Chelli, M.; Rovero, P.; 
Papini. A.M. Proc. Natl. Acad. Sci., U.S.A. 2005 102(29), 10273-10278. 
25  Lolli, F.; Mazzanti, B.; Pazzagli, M.; Peroni, E.; Alcaro, M.C.; Sabatino, G.; 
Lanzillo, R.; Brescia Morra, V.; Santoro, L.; Gasperini, C.; Galgani, S.; D’Elios, M.M.; 
Zipoli, V.; Sotgiu, S.; Pugliatti, M.; Rovero, P.; Chelli, M.; Papini, A.M. J 
Neuroimmunol. 2005, 167, 131-137 
26 Carotenuto, A.; D'Ursi, A. M.; Mulinacci, B.; Paolini, I.; Lolli, F.; Papini, A. M.; 
Novellino, E.; Rovero P. A. J. Med. Chem. 2006, 49, 5072-5079. 
27 Carotenuto, A.; Alcaro, M.C.; Saviello, M.R.; Peroni, E.; Nuti, F.; Papini, A.M.; 
Novellino, E.; Rovero, P. J. Med. Chem., 2008, 51, 5304–5309. 
28 Nuti, F.; Paolini, I.; Cardona, F.; Chelli, M.; Lolli, F.; Brandi, A.; Goti, A.; Rovero, 
P.; Papini, A.M. Bioorg. Med. Chem. 2007, 15, 3965-3973. 
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Figure 5. Calculated structures of CSF114(Glc). Ribbon diagram of the 
lowest energy conformer of 200 calculated structures of CSF114(Glc) derived 
from NMR data. 
Up to now, N-glucosylation, a post-translational modification not common in 
eukaryotic proteins, has been detected only in bacterial glycoproteins. 29 
Putative glucosylation of myelin proteins, by a still unknown mechanism, 
could transform self-antigens in non-self ones and triggering an autoimmune 
response. More than one protein could be aberrantly glucosylated creating a 
family of new autoantigens. Our hypothesis is that an aberrant N-glucosylation 
of myelin proteins could generate neoantigens no more recognized as self and 
for that reason triggering an autoimmune response. More than one protein 
could be aberrantly glucosylated and CSF114(Glc) could be a mimetic of all 
those glucosylated proteins. 
                                                     
29 Wieland, F.; Heitzer, R.; Schaefer, W. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 5470-
5474. 
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PART A: Glycopeptide antigen-antibody 
interaction in Multiple Sclerosis 
1. Characterisation of the epitope of the glycopeptide 
mimetic antigen: role of the sugar moiety and of its 
configuration linking to asparagine side chain  
Carbohydrates play an important role in biological function of glycoproteins. 
They can be involved in recognition signal, in cell adhesion, cell growth 
regulation, etc. Moreover, glycosylation is the most common co- or post-
translational modification of proteins in eukaryotic cells. Two main forms of 
protein glycosylation are naturally found: O- and N-glycosylation. Naturally 
occurring N-glycoproteins and N-glycopeptides are usually reported to present 
as first sugar an N-acetyl glucosamine N-β-linked to Asn side chain into the 
specific consensus sequence Asn-Xaa-Ser/Thr (where Xaa is any amino acid 
except Pro). The N-glycosidic bond links the glycan portion and the side chain 
of an asparagine residue. One exception is represented by nephritogenoside, a 
glycopeptide able to induce glomerulonephritis in its animal models,30 where 
the N-terminal sequence Asn-Pro-Leu is modified by a trisaccharide consisting 
of three O-linked glucosyl (Glc) residues, with N-α-Glc as the first sugar 
moiety linked to the Asn residue.31 
Following the hypothesis that an aberrant glycosylation could trigger 
autoantibodies in Multiple Sclerosis, different families of autoantibodies to 
proteins aberrantly glycosylated with different sugar moieties might be related 
to disease activity.24 Moreover, some authors reported of specific anti-
Glc(α1,4)Glc(α) identified in different MS patients suggesting an important 
                                                     
30 Shibata, S., Sakaguchi, H., and Nagasawa, T.; Nephron, 1976, 16, 241-245. 
31 (a) Shibata,S.; Takeda, T.; Natori, Y. J. Biol. Chem. 1988, 263, 12483-12485. (b) 
Takeda, T.; Sawaki, M.; Ogihara, Y.; Shibata, S. Chem. Pharm. Bull. 1989, 37, 54-56. 
PART A 
 22
role for glucose-based modifications in the pathogenesis of MS.32 These data 
have not yet been confirmed by other authors. 
In previous studies performed at PeptLab, we selected CSF114(β-Glc), as 
optimal Multiple Sclerosis Antigenic Probe (MSAP). CSF114(β-Glc) was 
developed by a screening of a CSF114-type glycopeptide library based on O- 
and N-β-glycosyl amino acid diversity (Glc, Man, GlcβGlc, Gal, GlcNAc, etc) 
tested in ELISA.33,28 Up to now, the role of different configuration, i.e. the α-
N-glucosyl moiety, has not been yet investigated, particularly because Fmoc-
Asn(αGlcAc4)-OH had never been synthesized before (Figure 1.1). For that 
reason, we devoted some efforts to the synthesis of this new building block 
useful for solid phase synthesis of CSF114(α-Glc). 
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Figure 1.1. N-glucosylated asparagine building blocks Fmoc-Asn(αGlcAc4)-
OH (A) and Fmoc-Asn(βGlcAc4)-OH (B) orthogonally protected for Solid 
Phase Peptide Synthesis. 
                                                     
32 Schwarz, M.; Spector, L.; Gortler, M.; Weisshaus, O.; Glass-Marmor, L.; Arnon 
Karni, L.; Dotan, N.; Miller, A. Journal of the Neurological Sciences, 2006, 244 59 – 
68. 
33 (a) Nuti, F.; Cicchi, S.; Peroni, E.; Pozo-Carrero, M. C.; Mazzanti, B.; Pazzagli, M.; 
Lolli, F.; Chelli, M.; Papini, A. M.; Brandi, A. Peptides 2002, E. Benedetti; C. Pedone 
(Eds.), Edizioni Ziino, Castellammare di Stabia, Italy, 238-239. (b) Nuti, F.; Paolini, I.; 
Mulinacci, B.; Pozo-Carrero, M. C.; Mazzanti, B.; Pazzagli, M.; Lolli, F.; Chelli, M.; 
Cordero, F. M.; Brandi, A.; Papini, A. M. Peptide Revolution: Genomics, Proteomics 
& Therapeutics. M. Chorev & T.K. Sawyer (Eds), American Peptide Society, San 
Diego, CA, USA 2004, 77-78. 
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1.1 Synthesis of N-α-glucosylated asparagine building 
block Fmoc-Asn(αGlcAc4)-OH 
1.1.1 State of the art 
In glycopeptide synthesis, much attention has to be paid to the stereoselective 
formation of the glycosidic bond which should survive during all the steps of 
peptide synthesis. The building block approach is up to now the most 
convenient one and therefore the most commonly used. In this case preformed 
glycosylated amino acid building blocks34 can be employed in the stepwise 
assembly of the peptide backbone. The use of anomerically pure glycosylated 
amino acid building blocks in Solid-Phase Glycopeptide Synthesis (SPGPS) 
guarantees the presence of a selective sugar linkage to the amino acid side 
chain in the glycopeptide. 
A variety of syntheses leading to β-N-linked amino acid building blocks are 
reported in the literature. 35  In particular, in previous studies performed in 
PeptLab we optimized large-scale synthesis of β-linked glycans to Asn and 
Gln side chains for a series of sugar moieties. In particular, thanks to 
microwave energy, the building block Fmoc-Asn(βGlcAc4)-OH [useful in the 
glycopeptide synthesis of CSF114(β-Glc)] was synthesized in a shorter time 
and in high yield compared to conventional approaches (Scheme 1).36 
                                                     
34 (a) M. Meldal, In: Neoglycoconjugates: Preparation and Application, ed. Y. C. Lee 
and R. T. Lee, Academic Press, Orlando, 1994, 145-198; (b) M. Meldal, Curr. Opin. 
Struct. Biol., 1994, 4, 710-718; (c) M. Meldal, K. Bock, Glycoconjugate J., 1994, 11, 
59-63. 
35 (a) Christiansen-Brams, I.; Meldal, M.; Bock, K.; J. Chem. Soc. Perkin Trans. 1, 
1993, 1461-1471. (b) Van Ameijde, J.; Albada, H.B.; Liskamp, R.; J. Chem. Soc. 
Perkin Trans. 1, 2002, 1042-1049. (c) Venkataramanarao, R.; Sureshbabu, V. 
SYNLETT, 2007, 16, 2492–2496. (d) Toshuki, I. 1994, patent  JP 93-77583 19930311. 
(e) Ying, L.; Liu, R.; Zhang, J.; Lam, K.; Lebrilla, C. B.; Gervay-Hague, J. J. Comb. 
Chem., 2005, 7, 372-384. 
36 Paolini, I.; Nuti, F.; Pozo-Carrero, M.C.; Barbetti, F.; Kolesinska, B.; Kaminski, 
Z.J.; Chelli, M.; Papini, A.M. Tetrahedron, 2007, 48, 2901-2904. 
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Scheme 1. Synthetic strategy to Fmoc-L-Asn(βGlcAc4)-OtBu 
On the other hand, the interest in developing a stereoselective synthesis of α-
N-linked glycosylated asparagine prompted us to investigate several strategies. 
In fact, up to now very few ones have been reported and none for this 
anomeric building block orthogonally protected for both Fmoc/tBu and 
Boc/Bzl SPGPS.  
Recently, the use of glycosylazides as starting reagent has replaced the 
traditional glycosylamines, classically used in the synthesis of the β-anomer, 
as a consequence of poor final stereoselectivity. 37  A method for the 
stereoselective synthesis of N-glycosylated asparagine, based on the traceless 
Staudinger ligation of glycosyl azide with pre-functionalized phosphines, has 
been reported.38 In this case, the α-glycosyl amide could be obtained only 
when hydroxyl functions of the glycosyl moiety were benzyl-protected. This 
synthetic strategy required two more steps to change sugar hydroxyl protecting 
groups from benzyl to acetate. 
Damkaci and DeShong proposed a straightforward strategy to obtain 
acetylated N-α-glucosyl asparagine by controlling the stereochemistry of the 
carbohydrate anomeric center via an isoxazoline intermediate. 39  In this 
approach, the stereochemistry of the isoxazoline intermediate should control 
                                                     
37(a) Staudinger, H.; Meyer, J. HelV. Chim. Acta 1919, 2, 635-646. (b) Gololobov, Y. 
G.; Kasukhin, L. F. Tetrahedron, 1992, 48, 1353-1407. (c) Kovács, L.; Ösz, E.; 
Domokos, V.; Holzer, W.; Györgydeák, Z. Tetrahedron 2001, 57, 4609-4621.  
38 Bianchi, A.; Bernardi, A.; J. Org. Chem., 2006,71 (12), 4565-4577. 
39 Damkaci, F.; DeShong, P. J. Am. Chem. Soc. 2003, 125, 4408-4409. 
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stereochemistry at the newly formed anomeric center. We followed this 
strategy to try to obtain the desired building block Fmoc-Asn(α-GlcAc4)-OH 
orthogonally protected for SPGPS. 
1.1.2 Synthesis of Fmoc-Asn(α-GlcAc4)-OH via 3,4,6-tri-O-acetyl-α-
D-glucopyranosyl isoxazoline intermediate. 
Damkaci and DeShong previously reported that treatment of either α- and β-
glucopyranosyl azides with Ph3P in refluxing 1,2-dichloroethane in the 
presence of 4Å molecular sieves for 15 h gave exclusively α-isoxazoline. 
During preparation of the isoxazoline (3) (Scheme 3), both α- and β-
glucopyranosylazide anomers (2) were used. Compound 2α was previously 
synthesized as reported in Scheme 2 and compound 2β is commercially 
available. 
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Scheme 2. Synthesis of α-glucopyranosylazide derivative 2a. 
First of all, we tried to improve the synthesis of the isoxazoline 3 by 
microwave (MW) technology.  
While MW-assisted synthesis is widely applied in other domains of organic 
synthesis, in the field of glycopeptide synthesis very few examples have been 
reported possibly because of the low stability of carbohydrates to thermal 
degradation.40 Several results in other fields show enhanced reaction rates and 
                                                     
40 (a) Das, S. K.; Reddy, K. A.; Abbineni, C.; Roy, J.; Rao, K. V. L. N.; Sachwani, R. 
H.; Iqbal, J. Tetrahedron Lett. 2003, 44, 4507. (b) Oliveiva, R. N.; Filho, J. R. F.; 
Srivastava, R. M. Tetrahedron Lett. 2002, 43, 2141. (c) Das, S. K.; Reddy, K. A.; Roy, 
J. Synlett 2003, 1607. (d) Mathew, F.; Jayaprakash, K. N.; Fraser-Reid, B.; Mathew, J.; 
Scicinski, J. Tetrahedron Lett. 2003, 44, 9051. 
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higher product yields as compared to conventional approaches.41 Generally 
speaking, the MW energy should mainly be related to heat effects, and many 
reports have focused on “improvement of reactions”. We applied our expertise 
in the microwave-assisted synthesis of the β-glucosyl anomer linked to the 
Asn side chain orthogonally protected for SPGPS, Fmoc-Asn(βGlcAc4)-OH,36 
to the synthesis of the corresponding α-anomer Fmoc-Asn(αGlcAc4)-OH. 
The isoxazoline 3 was successfully synthesized under MW conditions at 100W 
and 130ºC (Scheme 3). Thanks to MWs, the reaction time could be reduced 
from 15 h to only 10 min.  
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Scheme 3. Synthesis of 3,4,6-tri-O-acetyl-α-D-glucopyranosyl isoxazoline 3. 
In the literature, it was previously reported the synthesis of Z-Asn(αGlcAc4)-
OBn via acylation of the isoxazoline derivative 3 leading to N-α-peracetylated 
glucosyl asparagine protected at the α-amino function with a 
benzyloxycarbonyl group (Z) and at the α-carboxyl function as benzyl ester 
(Bn). In particular, Z-Asn(αGlcAc4)-OBn, was obtained using the asparagine 
residue modified on the side chain with mercaptopyridine, Z-Asp(SPy)-OBn 
(6), and CuCl2·2H2O as an additive at 30ºC in 24h.39 
Unluckily, Z-Asn(αGlcAc4)-OBn is not an useful tool for solid phase synthesis 
of glycopeptides. Moreover, Z and Bn are not orthogonal for SPPS. These 
                                                     
41 (a) Kappe, C.O. Angew. Chem. Int. Ed. 2004, 43 6250. (b) Kappe, C.O.; Dallinger, 
D. Nat. Rev. Drug Disc. 2006, 5, 51. 
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observations prompted us to perform several reactions to obtain N-α-
glycosylated amino acids orthogonally protected for SPGPS, in particular 
Fmoc-Asn(αGlcAc4)-OtBu (10α). Finally, we succeeded in performing MW-
assisted coupling reactions on differently protected aspartic acid derivatives 
(PG-Asp-OX) as acylating reagents (Table  1.1.1) with the isoxazoline 
derivative 3 (Scheme 4).  
In fact, by MW irradiation (100 W), the reaction was complete in less than 10 
min. maintaining the vessel temperature at 130 °C. 
O
AcO
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OAc HN
OAc
R1HN
OR2
O
O
100 W, 130 ºC, 10 min
1,2 dichloroethane
PG-Asp-OX
9: R1=Z, R2=Bn
10: R1=Fmoc, R2= tBu
O
AcO
AcO
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O
OAc
3
 
Scheme 4. Coupling reaction of 3,4,6-tri-O-acetyl-α-D-glucopyranosyl 
isoxazoline 3 with PG-Asp-OX.. 
Table  1.1.1. Coupling reaction conditions and reagents.a 
PG-Asp-OX equiv α/βb MW Protocol Yieldc 
FmocHN
OPfp
O
O
Cl
4
 
3 No product
P = 100W 
T = 130°C 
Time = 10min
- 
FmocHN
OtBu
O
O
HO
5
 
3 53/47 
P = 100W 
T = 130°C 
Time = 10min 
32 % 
FmocHN
OtBu
O
O
HO
5
 
1 52/48 
P = 100W 
T = 130°C 
Time = 10min
28% 
ZHN
OBn
O
O
PyS
6
 
1.3d 73/27 
P = 100W 
T = 130°C 
Time = 10min
78% 
FmocHN
OtBu
O
O
PyS
7
 
1.3d 56/44 
P = 100W 
T = 130°C 
Time = 10min 
43% 
aAll reactions were performed in a sealed vessel specific for the monomode microwave 
synthesizer CEM EXPLORER 48® in 1,2-dichloroethane using NMM, the coupling reagent 
DMT-NMM/BF4, and the acylating reagent PG-Asp-OX. Detailed protocol is reported in the 
Experimental Part A. bCalculated by HPLC analysis. cFor isolated product. dCuCl2·2H2O 
was added as an additive. Syntheses of PG-Asp-OX 4, 6, and 7 are described in details in 
the Experimental Part A. 
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While Z-Asp(Spy)-OBn in the coupling reaction maintained a good 
stereoselectivity also under MW conditions, the use of the Fmoc-protected 
aspartic acid derivative, Fmoc-Asp(Spy)-OtBu, significantly decreased 
stereoselectivity and reaction yield. For this reason, we developed a new 
strategy to obtain Fmoc-Asn(αGlcAc4)-OH. 
1.1.3 New synthetic strategy to Fmoc-Asn(αGlcAc4)-OH (11) 
We previously reported a MW-assisted synthesis of Fmoc-Asn(βGlcAc4)-
OtBu coupling glucosylamine (1 equiv) to aspartic acid side chain (1 equiv) in 
the presence of NMM (1 equiv) and the new efficient triazine-based coupling 
reagent DMT-NMM/BF4 [4-(4,6-dimethoxy-1,3,5-triazin-2-yl-)-4-
methylmorpholinium tetrafluoroborate] displacing the equilibrium of the 
coupling reaction and favouring formation of the final product (Scheme 1).42  
Therefore, we developed a new strategy for the synthesis of the corresponding 
α-glucosyl derivative Fmoc-Asn(αGlcAc4)-OH orthogonally protected for 
Fmoc/tBu SPGPS. We performed a series of coupling reactions changing 
different parameters (i.e., MW power, temperature, and reaction time) to set up 
the optimal conditions leading to the N-α-linked glucosyl derivative 10α. To 
the best of our knowledge, up to now no data were reported on temperature 
effect influencing stereoselectivity of N-glycosilic bond formed between 
amino sugars and the side-chain carboxyl function of Asp.  
 
                                                     
42 (a) Kaminski, Z.J.; Kolesinska, B.; Kolesinska, J.; Sabatino, G.; Chelli, M.; Rovero, 
P.; Blaszczyk, M.; Glowka, M.L.; Papini, A.M. J. Am. Chem, Soc. 2005, 127, 16912. 
(b) “Process for the preparation of N-triazinylammonium salts”. Filing date 
07/11/2005. Applicant: Italvelluti S.p.a. Inventors: Z. Kaminski, A. M. Papini, B. 
Kolesinska, J. Kolesinska, K. Jastrzabek, G. Sabatino, R. Bianchini. 
PCT/EP2005/055793 , 2005. (c) Kamiński, Z.J. Int. J. Pept. Protein Res., 1994, 43, 
312-319 
PART A 
 29 
O
AcO
AcO
OAc
H
N
OAc
FmocHN
O-tBu
O
O
10
O
AcO
AcO
OAc
NH2
OAc
8
coupling reaction
 
Scheme 5. Coupling reaction between 1-glucosylamine 8 and  
Fmoc-Asp-OtBu (5) 
The results are summarized in Table  1.1.2. The coupling reaction monitored 
by NMR and HPLC showed that in 5 min, at 70ºC, and 100 W the N-β-
glucosyl derivative 10β could be obtained and purified as an unique product 
(Table  1.1.2, entry 1). When temperature and MW power were increased, the 
α-anomer 10α started to form, with a maximum of α/β ratio 87/13 at 150ºC 
and 100 W (entry 8). Moreover, when MW power was increased from 100 W 
to 200 W (see entry 9) the α/β ratio reached 92/8. By decreasing coupling 
reaction time to 1 min, it was possible to avoid Nα-Fmoc deprotection because 
of high temperature. 
Table  1.1.2 Comparative study of different coupling conditions 
for amide bond formation between 1-glucosylamine and aspartic-
acid side chain to obtain N-α- and/or N-β-glucosyl derivatives 
10α/10β.  
Entry Temp
b 
(ºC) 
Timec 
(min) 
Power 
(W) 
Yieldd 
(%) 10α/10β
e 
1 70 5 100 80 6/94 
2 70 5 30 37 8/92 
3 70 1 300 52 26/74 
4 100 3 100 58 45/55 
5 100 3 150 63 50/50 
6 130 1 100 52 72/28 
7 130 1 200 58 85/15 
8 150 1 100 69 87/13 
9 150 1 200 76 92/8 
aAll reactions were performed in a sealed vessel specific for the monomode 
microwave synthesizer CEM EXPLORER 48® in acetonitrile using Fmoc-L-Asp-
OtBu, NMM, and the coupling reagent DMT-NMM/BF4 as starting materials. Protocol 
is described in details the Experimental Part A. bFor coupling reaction. cAt the 
temperature described. dFor isolated product. eCalculated by HPLC analysis. 
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All reaction conditions reported in Table  1.1.2 were also performed without 
microwave energy (data not shown). In that case only the N-β-glucosyl anomer 
10β could be obtained. Considering that we achieved in a limited number of 
steps, with a very good yield Fmoc-Asn(αGlcAc4)-OH by microwave 
irradiation, we can hypothesize that the α-anomer is the thermodynamically 
favoured compound (Figure  1.1.3). 
.  
Figure  1.1.3. Formation of the kinetic product P1 occurs under the faster 
reaction since it has a more stable transition state, TS1, and therefore a lower 
activation barrier. Thermodynamic product P2 is the more stable product 
since it is formed at lower energy than P1.  
In any case, playing with microwave energy, we can decide to obtain the α or 
the β-anomer36 in high yield and short reaction time.  
In conclusion, the N-glucosyl asparagine derivatives 10α and 10β could be 
successfully purified independently by Flash Column Chromatography. After 
deprotection of the α-carboxyl function by a TFA solution in DCM we 
obtained the two anomerically pure building blocks useful for SPGPS, Fmoc-
Asn(αGlcAc4)-OH (11α) and Fmoc-Asn(βGlcAc4)-OH (11β) orthogonally 
protected for Fmoc/tBu strategy. 
1.2 Synthesis of glycopeptide mimetics 
Fmoc-Asn(αGlcAc4)-OH (11α) and Fmoc-Asn(βGlcAc4)-OH (11β) were 
employed in the stepwise solid phase synthesis of the β-turn structure CSF114 
at position 7 (Table  1.2.1). 
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Table  1.2.1. Glycopeptide sequences 
Glycopeptide Sequence 
CSF114(αGlc) (Iα) TPRVERN(αGlc)GHSVFLAPYGWMVK 
CSF114(βGlc) (Iβ) TPRVERN(βGlc)GHSVFLAPYGWMVK 
 
Glycopeptides Iα and Iβ were synthesized on an automatic Prelude® 
instrument, starting from a Wang resin, according to the General Procedure for 
the SPPS described in details in the Experimental Part and using commercially 
available Fmoc-protected amino acids and HOBt/TBTU/NMM activation. The 
new building block Fmoc-L-Asn(αGlcAc4)-OH (11α) and Fmoc-L-
Asn(βGlcAc4)-OH (11β) were manually added using HOBt/TBTU/NMM 
activation. After cleavage of the glycosylated peptides from the resin and 
deprotection of amino-acid side chains, deprotection of the hydroxyl functions 
of sugars was performed as described in details in the Experimental Part using 
MeONa/MeOH. The glycopeptides were purified by semi-preparative HPLC 
and characterized by ESI-MS. Analytical data are reported in Table  1.2.2 
Table  1.2.2. Analytical data of glycopeptides. 
Peptide HPLC (Rt,min)a 
ESI-MS [M+2H]2+ 
Calc (found) 
Iα 14.82 1303.0 (1303.6) 
Iβ 14.83 1303.0 (1302.8) 
aAnalytical HPLC gradients at 1 mL min-1, 20-60% B in 20 min, 
solvent system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN; 
1.3 Immunochemical assays of CSF114(Glc) analogues 
The antibody recognition using the CSF114(Glc) glycopeptide analogues Iα 
and Iβ was evaluated by solid phase and competitive-ELISA on Multiple 
Sclerosis patients’ sera. The unglycosylated peptide CSF114 was employed as 
negative control.  
We evaluated, by SP-ELISA, serum antibodies (IgM and IgG class) to the 
glycopeptides Iα and Iβ in a group of MS patients and compared the results 
with Normal Blood Donors’ sera (NBDs). IgM and IgG responses were 
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detected using as secondary antibodies anti-human IgMs and anti-human IgGs 
conjugated to alkaline phosphatase. 
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Figure  1.3.1. Antibody titre in MS patients to glycopeptides CSF114(αGlc) 
and CSF114(βGlc). 
It is accepted that the glycopeptide Iβ CSF114(βGlc) detects specific 
antibodies in MS patients’ sera.24 In fact, as reported in Figure 1.3.1, the 
glycopeptide Iβ displays high antibody recognition, and the glycopeptide Iα is 
always able to detect antibodies showing a relative similar activity. 
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Figure  1.3.2. Inhibition curves of anti-CSF114(Glc) antibodies with the 
glycopeptides Iα and Iβ. Results are expressed as % of a representative 
Multiple Sclerosis positive serum (y axis). Concentrations of peptides as 
inhibitors are reported on the x axis. 
In competitive ELISA, the two glycopeptides displayed inhibitory activity at 
the same concentration. As reported in Figure 1.3.2, the two glucosylated 
peptides present similar IC50 value (concentration required for 50% 
inhibition). In conclusion, the glycopeptides containing the Asn(Glc) residue, 
independently of the anomeric configuration of the glucosyl moiety, showed 
similar high affinity to autoantibodies present in Multiple Sclerosis patients’ 
sera.  
Further NMR studies of glycopeptides Iα an Iβ could confirm the real 
configuration of the glucosyl moiety once linked into the peptide sequence. 
Cleavage and deacetylation conditions could modify the anomeric 
configuration or this could change because of possibly tautomeric forms. This 
hypothesis is supported by recent results reporting that in the case of glycated 
peptides tautomerization of the sugar moiety could be kinetically driven 
allowing less stable tautomers formation.43  
 
                                                     
43 Carganico, S.; Rovero, P.; Halperin, J.A.; Papini, A.M.; Chorev, M. J Pept Sci, 2008, 
published online 11 November 2008. 
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2. Modification of the glycopeptide antigen 
CSF114(Glc) with electrodetectable molecules to 
improve antibody detection 
In order to help clinicians to follow up Multiple Sclerosis patients by a simple 
blood test to detect autoantibodies, different problems have to be solved. In 
fact, the development of reliable and efficient diagnostic/prognostic assays for 
autoimmune diseases requires: 
1) Selection of the antigen recognising specific autoantibodies in a statistically 
significant number of patients (sensitivity) compared to other autoimmune 
diseases and normal controls;  
2) Selection of the diagnostic technique to detect autoantibodies (ELISA, 
radioimmunoassay, immunofluorescence, SPR, etc). 
In the case of Multiple Sclerosis, patients accumulate myelin lesions, but also 
axonal loss leading to permanent neurological dysfunctions. Magnetic 
Resonance Imaging (MRI) is up to now the most reliable technique to help 
clinicians not only in diagnosis, but also in prognosis because no gold standard 
simple immunoassays are available. However, it is evident that MRI cannot be 
considered a routine technique and that efficient autoantibody detection could 
be useful as signal of disease progression when the clinical symptoms are not 
still visible to guide a targeted MRI checkup.44  
Other diagnostics techniques exploit the capability of antibodies to detect 
analytes with high sensibility, specificity, and adaptability at very low levels. 
Therefore, immunoassays are based on an antigen/antibody interaction to 
identify a target compound or a class of compounds, as in the ELISA. 
Immunoassays take advantage of the ability of antibodies to bind selectively a 
target antigen present in a sample matrix and characterized by a specific 
chemical structure. Working like a key and lock, the binding sites on an 
                                                     
44 Vossenaar, E.R.; van Venrooij, W.J. Clin. Appl. Immunol. Rev. 2004, 4, 239-262 
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antibody attach precisely and non covalently to the corresponding target 
antigens.  
ELISA offers advantages, such as allowing simultaneous analyses of a large 
number of samples. To avoid non-reproducible or non-interpretable results 
because based on operator-dependent procedures, there is a need of diagnostics 
industry involved in the field of autoimmunity, not only for fast, but also for 
sensitive and more consistent techniques particularly for quantitative 
determination of autoantibodies to follow up disease activity.  
Electrochemistry as detection technique of biological and clinical assays is 
extremely interesting because it can shorten time analyses, increasing 
reliability. 
2.1 Ferrocenyl derivatives as electrochemical probes 
Glycopeptide analogues of CSF114(Glc), properly modified at N-terminus 
with new ferrocenyl and ferrocenyl-thiophosphine derivatives as 
“Electrochemical Probes”, were used in Cyclic Voltammetry measurements in 
solution and/or grafting peptides on a gold electrode. At this purpose, in the 
context of the cooperation with the Institut de Chimie Moléculaire (ICMUB) 
of the University of Burgundy (Dijon, France), new electrodetectable 
molecules have been designed. In particular, ferrocenyl and thiophosphine 
derivatives were selected as biosensors.  
Availability of a large variety of ferrocenyl derivatives and their favourable 
electrochemical properties (undergoing a reversible oxidation in aqueous 
solution) make ferrocene and its derivatives very trendy molecules for 
biological applications and for conjugation with biomolecules.45 Furthermore, 
ferrocenyl and thiophosphine derivatives are a new class of linkers useful for 
electrochemical and optical bio-detections. In this context, we decided to use 
                                                     
45 Van Staveren, D.R.; Metzler-Nolte, N. Chem. Rev. 2004, 104, 5931-5985. 
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ferrocenyl carboxylic acid and a new ferrocenylthiophosphine derivative of 
butyric acid (Figure  2.1). 
 
Figure  2.1. Structure of ferrocenyl derivatives used for SPPS. a) Ferrocenyl 
carboxylic acid [Fc-COOH] and b) (Sp,S)-(+)–2-(tert-butoxycarbonylamino)–
4-(ferrocenylphenylthiophosphino)butanoic acid [4-FcPhP(S)Abu]. 
The electrochemical properties of ferrocene coupled to thiophosphine ability to 
build simple monolayers on gold surfaces will let peptides anchoring on the 
working electrode used for detection. The possibility of grafting the synthetic 
probe directly on the electrode surface will enable to obtain an innovative 
strategy to develop new techniques for antibody detection opening new 
strategies in the analysis of antibody profiles in MS patients’ sera, possibly 
improving detection of a panel of antibodies as specific biomarkers for 
different forms of the disease. 
The new unnatural amino acid 4-FcPhP(S)Abu, protected for SPPS, was 
synthesized following the strategy previously developed at the University of 
Burgundy. 46  The ferrocenyl-thiophosphine derivative 4-FcPhP(S)Abu was 
obtained from ferrocene in 10 steps with global yield of 48% by reaction of 
(S)-ferrocenylphenylphosphine borane with the (S)-(-)-2-[bis(tert-
butoxycarbonyl)amino]-4-iodobutanoate47 and then subsequent sulfuration and 
deprotection gave desired amino acid derivative 4-FcPhP(S)Abu (Scheme  2.1).  
                                                     
46 Colson, A.; Bayardon,, J.; Rémond, E.; Lauréano, H.;  Nuti, F.; Meunier-Prest, R.; 
Kubicki, M.; Darcel, C., Papini, A.M., Jugé, S. J. Org. Chem. Submitted. 
47 The benzyl (S)-(-)-2-[bis(tert-butoxycarbonyl)amino]-4-iodobutanoate was prepared 
according a modified following procedure described in: Adamczyk, M.; Johnson, D.D.; 
Reddy, R. E. Tetrahedron: Asymmetry 2000, 11, 3063-3068. 
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Scheme  2.1. Synthesis of the modified amino acid (Sp,S)-(+)–2-(tert-
butoxycarbonylamino)–4-(ferrocenylphenylthiophosphino)butanoic acid [4-
FcPhP(S)Abu]. 
2.2 Synthetic strategy to labelled peptides 
A collection of labelled peptides was prepared by solid phase peptide synthesis 
(SPPS) using the Fmoc/tBu strategy (Table  2.2). The novel ferrocenyl peptides 
were synthesized modifying CSF114(Glc) and the corresponding 
unglucosylated sequence, both containing the original 21 amino acids and the 
designed ferrocenyl derivatives (Figure  2.1). The Nα amino function of the 
amino acid 4-FcPhP(S)Abu was Boc protected and the α−carboxylic functions 
of both derivates were free to be used directly in SPPS. 
Only few studies reported on the solid-phase synthesis of organometallic 
derivatives of peptides. In fact, decomposition of organometallic peptides and 
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secondary products of SPPS have usually affected final yield.48 Taking into 
account that microwave technology applied to SPPS is proposed as a valid 
support for enhancement of efficiency of coupling reactions in short times, this 
strategy was applied to synthesize the peptide sequences performing the 
syntheses with a microwave-assisted automatic solid phase peptide synthesizer. 
Microwave technology decreases chain aggregation during the syntheses, 
improves the coupling rates, and prevents side reactions in particularly 
difficult peptide sequences.49 
At the end of the peptide synthesis, Boc-protected organometallic unnatural 
amino acids were manually introduced at the N-terminus of the resin-bound 
glycopeptide I and unglucosylated peptide I’ to obtain the peptide collection 
reported in Table 1. 
Table  2.2. Analytical data from Ultra Performance Liquid Chromatography 
(UPLC). 
Peptide name Rt(min) 
Calculed 
mass 
Observed mass 
[M+2H]2+ 
CSF114(Glc) (I) 2.07a 2606.3 1303.6 
Fc-CSF114(Glc) (IV) 1.872b 2820.2 1411.2 
4-FcPhP(S)Abu-CSF114(Glc) (V) 1.833b 3015.5 1508.3 
CSF114 (I’) 1.96a 2444.2 1222.6 
Fc-CSF114 (IV’) 1.813b 2655.3 1329.8 
4-FcPhP(S)Abu-CSF114 (V’) 1.863b 2853.5 1427.4 
Gradients at 0.45 mL min-1: a 10-60% B in 3.5 min, b 20-70% B in 3.5 min (solvent 
system, A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN). 
 
The metallocene moieties were demonstrated to be stable during Fmoc-
deprotection, cleavage, and in the deacetylation conditions (pH=12) requested 
for deprotection of the hydroxyl groups of the sugar. However, the final 
                                                     
48 Chantson, J.T.; Verga Falza, M.V,; Sergio Crovella, S.; Metzler-Nolte, N. Chem. 
Med. Chem. 2006, 1, 1268–1274. 
49 Rizzolo, F.; Sabatino, G.; Chelli, M.; Rovero, P.; Papini, A.M. International Journal 
of Peptide Research and Therapeutics 2007, 13, 203-208. 
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ferrocenyl peptides could be safely obtained when phenol rather than water 
was used as scavenger in the final cleavage mixture for resin and amino acid 
side chains deprotection.48  
All the compounds were analyzed by UPLC-ESIMS and HPLC-ESIMS and 
purified by RP-HPLC (>95%) to be used for autoantibody detection. 
2.3 Immunoenzymatic assays of ferrocenyl peptides 
The glycopeptide CSF114(Glc) (I), designed as a type I’ β-turn around the 
minimal epitope Asn(Glc), guarantees an optimal exposure of the epitope for 
antibody recognition in the solid phase conditions of the ELISA plate on sera 
of MS patients. In fact, the CSF114(Glc)-based ELISA allows to recognize 
both IgM and IgG in sera of 30% of MS patients’sera.26 
We evaluated, by ELISA, serum antibodies (IgM and IgG class) to the new 
organometallic peptides and glycopeptides (Table  2.2) in a group of MS 
patients and compared the results with Normal Blood Donors’ sera (NBDs). 
IgM and IgG responses were detected using as secondary antibodies anti-
human IgMs and anti-human IgGs conjugated to alkaline phosphatase. 
The antibody recognition to CSF114(Glc) (I) was compared versus the 
ferrocenyl glycopeptides IV and V and the corresponding unglycosylated 
sequences I’, IV’, and V’ in a first group of patients’ sera affected by 
clinically definite MS using SP-ELISA. It is accepted that the glycopeptide 
CSF114(Glc) (I) detects specific antibodies in MS patients’ sera.24 In fact, as it 
can be observed in Figure  2.3.1, the glycopeptide I presented the highest 
antibody recognition, but the new ferrocenyl glycopeptides IV-V are always 
able to detect antibodies showing only a relative lower biological recognition. 
As expected unglycosylated peptides I’, IV’, V’ are always inactive. 
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Figure  2.3.1. Autoantibody recognition in MS patients’ sera and NBDs 
sera. IgM (A) and IgG (B) classes versus the ferrocenyl glycopeptides 
(IV–V) and the corresponding unglycosylated ones (I’, IV’, V’) 
compared to the glycopeptide CSF114(Glc) I. Data are reported as 
absorbance at 405 nm of sera diluted 1:100. 
Considering that SP-ELISA reflects essentially the relative affinity, which 
depends on the exposure of the minimal epitope in the solid phase conditions 
of the assay, we also investigated the absolute antibody affinity in a 
competitive ELISA based on inhibition of autoantibodies in solution. In a set 
of MS positive sera, ferrocenyl glycopeptides IV and V inhibited binding of 
autoantibodies to CSF114(Glc) (I), giving rise to similar inhibition curves. The 
data of a representative serum (Figure  2.3.2) show that the two modified 
glycopeptides IV and V exhibited equivalent affinity in competitive ELISA, 
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despite the differences of apparent affinity detected in SP-ELISA (Figure 
 2.3.1). These findings indicated that the new ferrocenyl glycopeptides share an 
epitope similar to the one presented by CSF114(Glc), and the presence of 
ferrocenyl and/or thiophosphine moiety at the N-terminus doesn’t influence 
antibody recognition. 
 
Figure  2.3.2. Inhibition curves of anti-CSF114(Glc) Abs with ferrocenyl 
glycopeptides II-III and with unglycosylated peptides I’, IV’, V’, in 
comparison with I in a competitive ELISA. The results are expressed as 
the percentage of absorbance of a representative MS serum (ordinate 
axis). 
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Therefore the glycopeptide CSF114(Glc) modified with the ferrocenyl amino 
acids is still able to detect and inhibit autoantibodies in MS patients’ sera and 
cannot detect any antibody tire in NBDs’ sera. 
2.4 Electrochemical measurements 
2.4.1 Grafting peptides on gold electrode 
The glucosylated ferrocenyl peptide 4-FcPhP(S)Abu-CSF114(Glc) (V) and the 
unglucosylated one 4-FcPhP(S)Abu-CSF114 (V’) were adsorbed on gold 
surface to form a self-assembled monolayer (SAM) via the sulphur atom. A 
mixture of 11-mercaptoundecanoic acid and decanethiol was used to block the 
uncovered surface. The modified electrodes are denoted Au-V for the 
electrode grafted with V and Au-V’ for the electrode grafted with V’. The 
electrochemical response of the ferrocenyl group was performed by Cyclic 
Voltammetry. Fe(CN)64- was used as catalyst to increase the electrochemical 
current.50,51,52,53 Figure  2.4.1 shows the electrochemical response of Au-V in a 
tween solution of Fe(CN)64-. When a solution of purified anti-CSF114(Glc) 
antibodies is added, the electrochemical response is shifted towards more 
positive potentials. The peak potential appears 46 mV more positive than that 
of the same solution without antibodies. 
                                                     
50 Creager, S. E.; Radford, P. T. J. Electroanal. Chem. 2001, 500, 21-9. 
51 Radford, P. T.; French, M.; Creager, S. E. Anal. Chem. 1999, 71, 5101-8. 
52 Radford, P. T.; Creager, S. E. Anal. Chim. Acta. 2001, 449, 199-209. 
53 Bergren, A. J.; Porter, M. D. J. Electroanal. Chem. 2006, 591, 189-200. 
PART A 
 44
 
Figure  2.4.1. Cyclic Voltammetry of Au-V in a tween solution containing 
LiClO4 0.1 M and Fe(CN)64- 9x10-4M (green curve) without antibodies 
and with a solution of purified anti-CSF114(Glc) antibodies at a final 
dilution of 1:1000 (blue curve). Scan rate 50 mVs-1. 
When the same experiment is repeated with Au-V’, i.e. with the electrode 
modified by unglucosylated peptide V’, which is not able to recognize 
autoantibodies, the results are completely different (Figure  2.4.2). The 
electrochemical response of Au-V’ doesn’t change significantly after addition 
of a solution of purified anti-CSF114(Glc) antibodies. The potential peak is 
even shifted by few millivolts toward more negative potentials. 
 
Figure  2.4.2. Cyclic Voltammetry of Au-V’ in a tween solution containing 
LiClO4 0.1 M and Fe(CN)64- 9.10-4M (green curve) without antibodies and 
with a solution of purified anti-CSF114(Glc) antibodies at a final dilution of 
1:1000 (blue curve). Scan rate 50 mVs-1. 
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2.4.2 In solution measurements 
The detection of interactions between autoantibodies and the ferrocenyl 
peptide, Fc-CSF114(Glc) (IV), i.e. without P=S anchor, was realized in 
solution. The gold electrode properly modified with 11-mercaptoundecanoic 
acid to avoid non specific interactions with the biological medium, was 
introduced in a tween solution containing both LiClO4 0.1 M and Fe(CN)64- 
9x10-4M and the ferrocenyl glycopeptide IV. Figure  2.4.3 shows the cyclic 
voltammograms before and after addition of purified anti-CSF114(Glc) 
antibodies.  
 
Figure  2.4.3. Cyclic Voltammetry of IV, 1.77 10-4M in a tween solution 
containing LiClO4 0.1 M and Fe(CN)64- 9.10-4M (black curve) without 
antibodies and (red curve) with a solution of purified anti-CSF114(Glc) 
antibodies at a final dilution of 1:1000. Scan rate 50 mVs-1. 
In the case of the glucosylated ferrocenyl peptide IV, the peak potential is 
shifted of 34 mV towards positive values by addition of anti-CSF114(Glc) 
antibodies. However, in this case, a study of the nature of the protective 
monolayer should be investigated to confirm the interest of the glycopeptide 
IV for autoantibody detection.  
Figure  2.4.4 summarizes the results. The glucosylated biosensor Au-V and the 
glucosylated ferrocenyl peptide IV in solution, shift of more than 30mV 
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towards positive values by addition of anti-CSF114(Glc) antibodies. This is 
indicative of detection of antigen-antibody interaction, and therefore of the 
presence of autoantibodies in the tested MS patients’ sera. The negative 
control realized with the unglucosylated biosensor (Au-V’) shows a very small 
potential shift in the opposite direction. 
 
Figure  2.4.4. Electrochemical immunoassay: Potential difference between the 
electrochemical response with and without purified anti-CSF114(Glc) 
antibodies at a final dilution of 1:1000 for (black) the biosensor Au-V, (red) 
its negative control Au-V´ , (green) the ferrocenyl glycopeptide IV in solution 
and (blue) its negative control IV' in solution. 
In conclusion, the new ferrocenyl peptides containing the unnatural amino acid 
4-FcPhP(S)Abu are able to detect specific anti-CSF114(Glc) antibodies by 
electrochemical technique. Moreover, thanks to the presence of thiophosphine, 
the modified glycopeptide 4-FcPhP(S)Abu-CSF114(Glc) (V) is able to build 
simple monolayers on gold surfaces and it can be useful for antibody detection 
and quantitative determinations. The possibility of grafting these new 
ferrocenyl glycopeptides, as synthetic antigenic probes, directly on the 
electrode surface (as a valid alternative analytical method to detect 
autoantibodies in sera of MS patients) is currently under investigation in our 
laboratories. 
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We demonstrated the possibility of detecting isolated antibodies by Cyclic 
Voltammetry in samples containing 1:1000 diluted antibodies. This detection 
limit is in any case lower compared to the one set up in our validated ELISA 
on sera.24,25 Therefore, we are confident that this new voltammetry-based 
technique could be useful in detecting antibodies in sera of Multiple Sclerosis 
patients. 
.
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3. Identification of antibodies by Surface Plasmon 
Resonance  
The most commonly applied techniques for antibody detection exploit the 
characteristic of antibodies to bind selectively to a target antigen. These are 
Enzyme-Linked ImmunoSorbent Assay (ELISA), RadioImmunoAssay (RIA), 
or Fluorescent ImmunoAssay (FIA)  
An attractive and complementary method for measuring antigen-antibody 
interactions is Surface Plasmon Resonance (SPR). The SPR response is 
correlated to changes in refractive index at a sensor chip surface, caused by 
concentration changes, e.g. resulting from binding of an antibody to an 
immobilised antigen. Study of interactions between biomolecules can be 
monitored continuously allowing real-time measurements. The on-line 
monitoring may facilitate information regarding for example the specificity of 
the interaction between an immobilised antigen and its target molecule. 
Furthermore, information regarding the kinetics of the interaction, the strength 
of the interaction, and the concentration of the interacting species can also be 
obtained.54 
Therfore we investigated antigen-antibody interaction in Multiple Sclerosis by 
Surface Plasmon Resonance, using Biacore T100 instrument for real-time 
detection of anti-CSF114(Glc) antibodies in serum. 
3.1 Synthetic biotinylated glycopeptides for 
autoantibody recognition in Multiple Sclerosis 
patients’ serum  
In order to improve signal response in SPR studies, the glycopeptide probe 
CSF114(Glc) and the unglucosylated one CSF114, as synthetic antigens, were 
                                                     
54 Malmqvist, M.; Karlsson, R. Current Opinion in Chemical Biology, 1997, 1(3), 378-
383. 
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modified at the N-terminus with a biotinylated residue. Immobilization of 
peptide antigens via the biotin/avidin complex apparently represents an 
approach superior to the direct adsorption of low mass antigens on a surface.55. 
At this purpose, biotinylated peptides CSF114(Glc) and CSF114 were 
synthesized by Fmoc/tBu SPPS. Peptides were synthesized in an automatic 
Prelude® instrument starting from a Wang resin, according to the General 
Procedure for SPPS described in details in the Experimental Part and using 
Fmoc-amino acids and HOBt/TBTU/NMM activation. The peptide sequences 
were modified at the N-terminus introducing manually biotinyl-6-
aminoesanoic acid in SPPS by HOBt/TBTU/NMM activation. 
Table  3.1. Analytical data of biotinylated peptides. 
Peptide HPLC (Rt,min)a 
ESI-MS [M+3H]3+ 
Calc (found) 
Biotin-CSF114(Glc) (II) 14.7 982.6 (982.83) 
Biotin-CSF114 (II’) 18.4 929.3(929.7) 
aAnalytical HPLC gradients at 1 mL min-1, 20-60% B in 20 min, solvent system A: 
0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
Both Peptides II and II’ were contemporary cleaved from the resin and 
deprotected on the amino-acid side chains by using a mixture of 
TFA/ethanedithiole/thioanisole/H2O/phenol (92:2:2:2:2). In the case of 
glycopeptide II deprotection of the hydroxyl functions of the glucosyl moiety 
was performed as described in details in the Experimental Part using 
MeONa/MeOH. The peptides were purified by semi-preparative HPLC and 
characterized by ESI-MS. Analytical data are reported in Table  3.1.  
                                                     
55 Moroder, L.; Papini, A.M.; Siglmuller, G.; Kocher, K.; Dorrer, E.; Schneider, C. 
Biol. Chem. Hoppe-Seyler, 1992, 373, 315-321. 
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3.2 Antigen-antibody interaction study in Multiple 
Sclerosis patients’ serum by Surface Plasmon 
Resonance 
BIAcore monitors in real time, with a microfluidic system on a sensor surface, 
binding interactions between molecular partners such as antigen-antibody. A 
sensor surface was prepared by immobilising the synthetic glycopeptide 
CSF114(Glc) using two different strategies: direct immobilisation on dextran 
CM5 chip [amino coupling of CSF114(Glc)] and immobilisation on a 
previously activated steptavidin dextran CM5 chip with bioitin-CSF114(Glc) 
(II) (Table  3.2). 
Traditionally, BIAcore is considered an inappropriate technology for serum 
diagnostics because it is extremely difficult to subtract unspecific adsorption 
(with no relevant recognition properties) from the immunosensor surface. This 
is a particular critical point in the case of complex biological systems, e.g. sera 
samples. The difficulties in setting up of a reference surface with similar 
physical-chemical properties were overcome using the unglucosylated peptide 
CSF114, which lacks of activity. Therefore, all the unglucosylated peptide 
sequences were used on the reference surface for subtraction of unspecific 
binding or buffer effects. Unglycosylated peptides were captured on the 
reference channels (Fc1 and Fc3) and the corresponding glycosylated peptide 
sequences at the same level on active channels (Fc2 and Fc4).  
Table  3.2. Summary of immobilization procedures. 
 
A first study was realized with specific anti-CSF114(Glc) antibodies, 
previously purified as described in the Experimental Part and characterised in 
Immobilisation Flow cell Immobilised ligand Absolute response 
Direct amino coupling FC1 FC2 
CSF114 
CSF114(Glc) 
1063 RU 
950 RU 
Biotin/streptavidin FC3 FC4 
biotin-CSF114 
biotin-CSF114(Glc) 
453 RU 
766 RU 
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ELISA to establish their antigen recognition properties. The antibodies were 
hence used for optimisation of the sensor. Purified antibodies solution was 
fluxed on the channels for 3 min at 30μl/min. Immunosensor surface 
regeneration was carried out using solutions of glycine in HCl at pH = 2.0 at 
different concentrations. Antigen-antibody recognition is reported as relative 
response in Figure  3.2.1. 
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Figure  3.2.1. Bart chart reporting the relative response of the purified 
antibodies interacting with CSF114(Glc) (I) and its biotinylated derivative 
(II)(dilution 1:100). 
If the CSF114(Glc)-immobilization absolute response is higher using the 
amino coupling procedure, the relative signal response in the presence of 
antibodies is lower than expected. On the contrary, biotinylated peptides 
allowed to observe an increase of the signal by using the streptavidin-biotin 
immobilisation. This effect was likely because of a favoured CSF114(Glc) 
exposition on the sensor surface, improving the signal response in the biotin-
streptavidin system.56 The amino coupling binding to the activated dextran 
layer might occur in two different positions. In fact, CSF114(Glc) presents two 
free amino functions, one at the N-terminus and the other on Lys-21 side chain. 
                                                     
56 Bulukin, E. Biosensor Development for Food and Environmental Applications, 2006, 
PhD Thesis, Università degli Studi di Firenze. 
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Consequently, the minimal fundamental epitope Asn7(Glc) might not be 
optimally exposed for antibody interaction. Moreover, surface capacity in the 
two cases is different since streptavidin could bind up to four biotinylated 
antigen molecules. The different binding capacity in the two cases might 
significantly influence the sensitivity of recognition.  
The chip containing Biotin-CSF114(Glc) (II) was then used for the analysis of 
MS patients’ sera. Single sample serum from one MS patient, MS14, resulting 
positive in ELISA, was used to optimize the signal at dilution 1:100. We tested 
both directly injected serum MS14, and anti-human IgG (1:100) after MS14 
serum injection (Figure  3.2.2).  
0
10
20
30
40
50
60
70
80
MS 14 MS 14 + anti IgG
Bart Chart
R
el
at
iv
e 
re
sp
on
se
 (R
U
)-s
ta
bi
lit
y
Sample name  
Figure  3.2.2. Comparison of relative responses of the immunosensor in 
absence and in presence of anti-human IgG (to enhance antibody recognition 
signal). 
Time per assay was 20 min, hence a rapid screening. Signal was optimized 
thanks to injection of anti-human IgG after the serum sample. In fact, we 
obtained a four times increased recognition signal.  
After set-up of injection conditions, a series of analyses of Multiple Sclerosis 
patients’ sera (MS, 12) and normal blood donors (NBD, 20) was performed. 
Samples sera were diluted 1:100 before injection on the modified chip surface. 
The signal for each serum was obtained as difference between the control 
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channel with immobilised Biotin-CSF114 (flow cell 3) and Biotin-
CSF114(Glc) channel (flow cell 4).  
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Figure  3.2.3. Analyses of MS patients sera and normal blood donors (NBD). 
Results reported in Fig. 3.2.3 indicate that the system is able to distinguish 
between MS patients and NBDs. Differences between positive and negative 
samples were significant and allowed to establish a cut-off value.  
Moreover, results obtained with the immunosensor we developed in this study 
were compared with the ones obtained in ELISA. Comparison between 
BIAcore and ELISAs was carried out using the relative response and the IgG 
absorbance values respectively, on sera diluted 1:100 (Figure  3.2.4).  
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Figure  3.2.4. Comparison between BIAcore response (RU) and ELISA 
(Absorbance) for anti-CSF114(Glc) IgG detection. 
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The results indicate that the new immunosensor for BIAcore analysis was able 
to distinguish between normal blood donors and MS patients (Figure  3.2.3). 
Furthermore, the biosensor seems to correctly estimate the positive control 
sample MS31 that on the contrary resulted a false negative in ELISA. 
Moreover, false positive samples in ELISA, i.e., DS25 and DS27, resulted 
negative in BIAcore analysis (Figure  3.2.4).  
In conclusion, we can assess that in Multiple Sclerosis patients’ sera antigen-
antibody interaction can be efficiently detected by BIAcore technology 
compared to ELISA method. Moreover, BIAcore technology was able to 
improve antibody recognition in sera compared to ELISA. In fact, we were 
able to distinguish MS patients and normal blood donors by BIAcore using the 
newly developed immunosensor based on Biotin-CSF114(Glc). In addition, 
sera samples in ELISA need overnight incubation compared to immunosensor 
analysis, which can be performed in real-time with antibody detection in less 
than 20 minutes for each serum with a significant decrease of time analysis. 
Moreover, BIAcore analysis using the new Biotin-CSF114(Glc)-based 
immunosensor could be a promising technology compared to ELISA because 
it was able to avoid false negative and false positive controls. Further studies 
on a large number of samples (possibly a statistically significant number of 
MS and NBDs samples) will be able to confirm these very promising results. 
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4. Real-time measurements of antigen-antibody force 
interactions in Multiple Sclerosis by Optical 
Tweezers 
Binding and interaction studies between different classes of molecules are 
generally analysed in bulk solution samples, as it occurs for example in ELISA 
and SPR. A large number of molecules can be analysed at the same time in 
this kind of assay, and the system is in thermodynamic equilibrium where the 
molecules are exposed only to thermal forces. In recent time, however, a 
number of novel techniques have been developed, which are able to analyze 
interactions between individual pairs of molecules. Scanning probe 
microscopy, 57  optical tweezers, 58  biomembrane force probe, 59  and flexible 
micro needles 60  techniques have been used to investigate biomolecular 
interactions.  
Recently, Optical Tweezers (OT) have been particularly successful to 
investigate a variety of biological systems. This technique is able to directly 
measure forces on trapped objects. In fact, in OT experiments, a micrometer 
sized bead with high refractive index is trapped by optical forces in an electric 
field gradient near a laser focus. 61  Because the optical trap works as a 
mechanical potential well and displays virtual spring properties, forces can be 
measured following bead displacement from its equilibrium position in the 
trap centre. OT are typically compliant (<1 pN/nm) and possess a force 
resolution in the sub-picoNewton (pN) range. Moreover, the maximal trapping 
                                                     
57 Binnig, G.; Quate, C.F.; Gerber, C. Physical Review Letters, 1986, 56(9), 930-933. 
58  (a) Ashkin, A.; Dziedzic, J.M.; Bjorkholm, J.E.; Chu, S. Optics Lett, 1986, 11(5), 
288-290. (b)Gordon, J.P. Physical Review A, 1973, 8(1), 14-21. 
59 Evans, E.; Ritchie, K.; Merkel, R. Biophys J,  1995, 68(6), 2580-2587. 
60 Essevaz-Roulet, B.; Bockelmann, U.; Heslot, F. Proc Natl Acad Sci USA, 1997, 94, 
11935-11940. 
61 (a) Ashkin, A. Proc Natl Acad Sci USA, 1997, 94, 4853-4860. (b) Ashkin, A.; 
Dziedzic, J.M. Science, 1987, 235(4795), 1517-1520. (c) Ashkin, A.; Dziedzic, J.M.; 
Yamane, T. Nature, 1987, 330, 769-771. 
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force is typically smaller than 200 pN. In fact, it is determined by several 
factors, i.e., the diameter and refractive index of the bead, the numerical 
aperture and geometry of the optical system, and the incident optical power.62 
Optical tweezer is a recent technique able to study binding and/or adhesion of 
biomolecules in real time under biologically relevant conditions. 
In order to measure the forces necessary to break antigen-antibody formed 
bonds, when possible at the single-molecule level, the mechanics and 
mechano-chemistry of the interaction have been studied by Optical Tweezers. 
For this purpose, design and synthesis of molecular handles for grabbing 
purified antibodies from Multiple Sclerosis patients’sera specific for the 
glycopeptide antigen CSF114(Glc), had to be developed for manipulation in 
the Optical Tweezers instrument. 
4.1 Design and synthesis of optically labelled 
CSF114(Glc)-glycopeptide analogues for Optical 
Tweezers measurement.  
The glycopeptide CSF114(Glc) and the unglycosylated one have been 
appropriately modified to be employed in Optical Tweezers technology. To 
this purpose, glycopeptide antigen required a functional group, possibly far 
away from the epitope, which could be covalently linked to beads. Therefore, 
we used a Biotin-PEG-NovaTag™ resin as a solid support for SPPS. This 
resin incorporated a PEG spacer between Biotin and the peptides and 
glycopeptides to be synthesized. 
Peptides were synthesized following the Fmoc/tBu SPPS strategy, as described 
in details in the Experimental Part, using commercially available Fmoc-amino 
acids and HOBt/TBTU/NMM activation. Peptides were targeted at the N-
terminus with fluorescein introduced to differentiate, in Optical Tweezers 
                                                     
62 For more details about optical tweezers see chapter concerning description of the 
techniques in the experimental part. 
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procedure, beads containing peptides by fluorescence imaging. For this reason, 
after having synthesized the desired peptide sequences, 5(6)-
carboxyfluorescein was manually introduced at the N-terminus of the resin-
bound biotinylated peptides using HOBt/DIPCDI as coupling reagents. 
Table  4.1 Analytical data of fluorescent-labelled peptides. 
Peptide HPLC (Rt,min) 
ESI-MS [M+3H]3+ 
Calc (found) 
Fluoresceinyl-CSF114(Glc)-Biotin (III) 12.3a 1187.9 (1188.83) 
Fluoresceinyl-CSF114-Biotin (III’) 14.7b 1078.3 (1078.7) 
aAnalytical HPLC gradients at 1 mL min-1, 35-75% B in 30 min, 30-60% B in 30 min, solvent system A: 
0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
After cleavage from the resin and deprotection of the side chains of the peptide 
sequences using the scavenger cocktail TFA/H2O/EDT/phenol/anisol 
(92:2:2:2:2), final deprotection of the hydroxyl functions of the sugar moiety 
linked to Asn residue (using MeONa/MeOH) in the case of the glycopeptide 
III, as described in details in the Experimental Part, all the peptides were 
purified by semi-preparative HPLC and characterized by ESI-MS. Analytical 
data are reported in Table  4.1. 
4.2 Functionalization of the microscopic beads 
Specific anti-CSF114(Glc) purified antibodies were attached to functionalized 
anti-human IgG polystyrene (latex) beads. Unbound antibodies were removed 
after gently washing in D-PBS buffer. Detailed procedure is reported in details 
in the experimental part.  
Subsequently, streptavidin-coated latex beads were coated with biotinylated 
Fluoresceinyl-CSF114-Biotin and Fluoresceinyl-CSF114(Glc)-Biotin 
respectively. The PEG spacer introduced between peptide and biotin at the C-
terminus reduces steric hindrance between the peptide and the avidin leading 
to better binding of biotin. Furthermore, if binding of antigen-antibody pairs 
are close enough, adjacent antigens could form a new bond only when the 
existing linkage has ruptured. Tethering the peptide to the bead by a spacer can 
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be helpful for interactions because it can reduce these steric hindrance (Figure 
 4.2).63  
 
Figure  4.2. Schematic representation of adhesion between two microspheres, 
mediated by receptor-ligand bonds. In one case (left) the ligand was attached 
directly to the microsphere, which restricted the orientation of the ligands and 
resulted in strained bonds when multiple bonds were formed. In the other case 
(right) the ligand was attached to the microsphere by a tether, allowing 
greater freedom of orientation of the ligands to form multiple unstrained 
bonds. 
4.3 Real-time antigen-antibody interaction 
measurements 
In collaboration with Prof. V. Lombardi (Laboratorio di Fisiologia, 
Dipartimento di Biologia Animale e Genetica, Università degli Studi di 
Firenze), forces necessary to break bonds formed between the modified 
mimetic glycopeptide antigen III and IgG antibodies have been studied. 
Considering that the sensibility of the sophisticated instrument control and 
data acquisition of the optical tweezers should be absolutely necessary for 
reliable measurements, the apparatus interface had to be previously calibrated 
(Figure  4.3.1). 
                                                     
63 Kulin, S.; Kishore, R.; Hubbard, J.B.; Helmerson, K. Biophysical Journal, 2002, 83, 
1965-1973. 
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Figure  4.3.1. Image of the Optical Tweezers instrument. Colour lines indicate 
the different optical trajectories (blue: brightfield, red: trapping lasers, green: 
fluorescence excitation, magenta: fluorescence emission). 
All measurements were made inside a home-made microchamber. In order to 
withstand the fluid pressure, the chamber was sealed by melting the parafilm 
layers pressed between two coverglasses. A micropipette and 80-µm-diameter 
glass tubes were placed between the two parafilm layers prior to sealing. The 
chamber was clamped on a holder with two aluminium brackets with threaded 
holes to connect tubing to the chamber by means of flangeless fittings. 
Polystyrene beads of 1-10 µm diameters can be held on the tip of the pipette 
by suction. A syringe attached to the other end of the micropipette tubing was 
used to apply suction and pressure in the pipette. Two gravity-controlled 
containers were attached to the other end of the two tubes to introduce in the 
flow cell both isolated antibody and antigen molecule covalently attached to 
different polystyrene beads. 
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CSF114(Glc)-coated beads were flown in the microchamber, and one bead 
was captured with the glass micropipette controlling by fluorescence that the 
peptide was really attached (Figure  4.3.2). Furthermore, fluorescence intensity 
signal registered the peptide density into the bead. 
 
Figure  4.3.2. Fluorescence image of CSF114(Glc)-coated microbead.. 
Antibody-coated beads were entered into the chamber, and one bead was 
captured in the optical trap. Moving the micropipette towards the trap, the two 
beads were pressed together (Figure  4.3.3i). The beads were held pressed 
together for a pre-adjusted period. Subsequently, the micropipette was pulled 
away from the trap (Figure  4.3.3ii) with a preadjusted velocity. We measured 
the force at the instant that the connection between the two beads was ruptured 
(Figure  4.3.3iii).  
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 ii iiii
 
Figure 4.3.3. Picture sequence of the experimental procedure for measuring 
interaction forces. On the top, antibody-coated bead captured in the optical 
trap. The lower bead is the CSF114(Glc)-coated bead held with a moveable 
glass micropipette. The beads were first pressed together (i), then pulled apart 
(ii) until a rupture event occurred followed by the sudden return of the upper 
bead to its equilibrium position in the trap centre (iii). 
Characteristic force versus time traces obtained in antigen-antibody interaction 
force spectroscopy experiments is shown in Figure  4.3.4. Positive forces 
correspond to interaction forces, and negative forces to compression forces 
with which the beads were pressed together.  
 
Figure  4.3.4. Time-dependent force trace of interaction between a bead coated 
with CSF114(Glc) and a bead coated with isolated anti-CSF114(Glc) IgG 
(rigor bond). 
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In the force spectrum reported in Figure  4.3.4 we can observe tooth-shaped 
peaks consisting of a rising slope, a peak, and a rapid force drop. Force 
increases during stretch because interactions formed between antigen and 
antibody during the compression period hold the beads together. The peak 
corresponds to the force in the instant of the rupture of antigen-antibody 
interaction. This rupture force, which is an important parameter of the 
mechanical properties of the antigen-antibody interaction, was measured under 
various experimental conditions.  
To assure that the observed force spectra was certainly because of interaction 
between the synthetic antigen CSF114(Glc) and purified antibodies, several 
negative control experiments have been performed. First, the adhesion 
experiment was carried out using both microspheres processed with IgG 
antibodies (Figure  4.3.5A). No attachment was observed. In a second series of 
experiments, we studied possible adhesions between spheres coated with the 
isolated antibodies and spheres containing the fluoresceinyl derivative of the 
unglycosylated peptide CSF114 III’, used as negative control in ELISA due to 
its well known lack of activity (Figure  4.3.5B).. Adhesion was observed only 
in the case of the glucosylated peptide analogue III interacting with antibody-
coated spheres. Moreover, previous studies guarantee the resistance of 
streptavidin-biotin bond at forces exceeding 60 pN, which far exceed forces 
range in which antigen-antibody rupture events were observed in different 
systems.64  
                                                     
64  Bianco, P. Mechanics of titin-actin interaction explored with force-measuring 
optical tweezers, PhD Thesis, 2006, Università degli Studi di Firenze.  
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Figure  4.3.5. Collection of force traces obtained in control experiments: A. 
Control experiment between beads coated with isolated anti-CSF114(Glc) IgG 
antibodies, respectively; B. Control experiment between beads coated with 
isolated anti-CSF114(Glc) antibodies and CSF114 (III’), respectively. 
4.4 Rupture force statistic study of CSF114(Glc)-anti-
CSF114(Glc) IgG antibodies 
A hundred series of beads-touching were performed allowing a statistical 
study of the rupture forces distribution for the synthetic antigen CSF114(Glc) 
and anti-CSF114(Glc) IgG antibodies at different stretch rates. Figure  4.4.1 
reports the probability of the rupture force value.  
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Figure  4.4.1. Distribution of rupture forces of CSF114(Glc) – anti-
CSF114(Glc) IgG antibodies in the case of 5000 nm/s stretch rates(A) and 250 
nm/s (B). No-interaction probability is 66% (A) and 53% (B). 
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At a stretch rate of 5000 nm/s a relatively wide distribution is observed, with 
rupture forces ranging from 3.5 to 28 pN. Zero-rupture force value (no 
interaction) had the maximum probability value higher than 60% as expected 
(Figure  4.4.1A).  
Decreasing stretch rate to 250 nm/s resulted in widened rupture force range 
from 3.5 to 48 pm (Figure  4.4.1B). Moreover, rupture force event probability 
was increased from 40% to 50% probably because contact-time between beads 
increased. 
Intensity peak at ~3.5 pN (Figure  4.4.1B) could be explained at the single 
molecular level, which might correspond to the single antigen-antibody 
rupture force. The wide range of forces could be due to the interaction of 
multiple antibody molecules with different coated-antigens. Supporting 
previously reported hypotheses, all the experimental rupture force values are 
approximately multiple of 3.5 pN. Considering the experimental error, it is 
possible to establish a rupture force value for antigen-antibody interaction at 
the single molecular level: 3.5 ± 1 pN.  
In conclusion, a platform to study single-molecule interactions between the 
glycopeptide antigen CSF114(Glc) and its specific antibodies isolated from 
MS patients’ sera has been set-up. This platform let us to obtain the force 
value necessary to break antigen-antibody linkage. 
 
PART B 
 67 
PART B: Study on molecular mechanisms of 
autoantibody recognition in Multiple Sclerosis 
In order to characterize the molecular mechanism of autoantibody recognition 
in Multiple Sclerosis, it is necessary to investigate the structural aspects 
involved in autoimmune response. In Multiple Sclerosis, possibly native 
proteins protruding from the surface of myelin membrane are no more 
recognized as self-antigens and are involved in an autoimmune response. The 
structure-based designed glycopeptide CSF114(Glc) previously developed in 
our laboratories, is able to recognize high antibody titre in sera of Multiple 
Sclerosis patients. These results were validated in a simple immunoenzymatic 
assay on a statistical significant number of MS patients’sera compared to other 
immune diseases.25 Therefore, CSF114(Glc) works like a mimetic molecule of 
different epitopes produced in native myelin proteins. For this reason, we 
decided to investigate the behaviour of the glycopeptide antigen CSF114(Glc) 
in a membrane environment. By electrochemical measurements of the 
glycopeptide activity in a membrane model system, it could be possible to 
obtain detailed information about its behaviour in a membrane environment. 
5. Bilayers mimicking biological membranes 
5.1 Cells natural barrier 
To stay alive, all living cells need membranes. Membranes typically define 
enclosed spaces or compartments in which cells could maintain a chemical or 
biochemical environment that differs from outside. Membranes not only 
sustain cell, but have an active role in regulating flux of molecules, ions, and 
signals from one side to the other, preventing undesirable agents from entering 
cells. Probably the most important feature of a biological membrane 
(biomembrane) is its selective permeability. This means that the size, charge, 
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and other chemical properties of atoms and molecules attempting to cross it 
will determine whether they succeed to do so. Selective permeability is 
essential for effective separation of a cell or organelle from its surroundings.  
To understand membrane it is necessary to know its organization. All 
membranes have a general common structure, in which two-layered sheet of 
lipids have different molecules (glycoproteins, cholesterol, etc) embedded in 
them. Membrane formation is a consequence of the amphipathic nature of 
lipids. In aqueous environment the polar head groups face water, whereas the 
hydrocarbon tails interact with each other. The lipids, proteins, and other 
molecules are held together mainly by non-covalent interactions organized as 
fluid mosaic model.65 This model describes the cellular membranes as two-
dimensional, viscous solutions of lipids and proteins at thermodynamic 
equilibrium. Recently, this model system has been updated,66 assuming the 
non-randomness distribution of lipid and protein components in a membrane, 
which is characterized by variable patchiness, and thickness, and higher 
protein occupancy than it was generally considered before (Figure  5.1).  
 
Figure 5.1 Diagram of various classes of proteins associated with the lipid 
bilayer 
                                                     
65 Singer, S.J., Nicolson, G.L. Science, 1972, 175, 720-731. 
66 Engelman D.M. Nature, 2005, 438, 578-580. 
PART B 
 69 
5.2 Why mimicking a biological membrane? 
The complexity of the lipid bilayer system has made the biological membrane 
an extensive and exciting field of study. In particular, many researchers have 
focused the attention on membrane proteins. In fact, one of the major 
challenges in biosciences today is mimicking a bilayer lipid membrane to 
investigate membrane-related processes like cell adhesion, nerve excitation, 
photosynthesis, respiration etc. Biomimesis has represented a prominent 
concept in biosciences. As a consequence, biomimetic membranes represent a 
model that does not just copy biological membranes, but use the fundamental 
ideas and principles from biology, in a simplified approach. The biological 
membranes obey the laws of physics and chemistry. To explain a biological 
system such as a biomembrane in physical, chemical and physiological terms, 
as well as the behaviour of single proteins, it is necessary to employ a 
simplified model system. 
5.3 Biomimetic membranes: model systems 
The first membrane models to be studied were the bilayer lipid membranes 
(BLMs). 67  These planar membranes were obtained by spreading a lipid 
solution in a small hole (1 mm diameter) of a teflon septum separating two 
compartments, which contain an aqueous buffer. Evaporation or diffusion of 
the lipid solvent leads to thinning of the film across the small hole to its final 
bilayer state. Because of the lack of light reflectance, they are also called black 
lipid membranes. 
Concurrently with the development of the BLMs, other researchers studied the 
behaviour of free lipids in aqueous solutions. According to electron 
microscope experiments, they observed that lipids spontaneously formed a 
                                                     
67 Mueller, P., Rudin, D.O., Tien, H.T., Wescott, W.C. J. Phys. Chem,. 1963, 67, 534-
535. 
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closed bilayer membrane in aqueous environment.68 This structure, the so-
called liposome, was proven highly useful in a number of studies on 
membrane structure and function, in which proteins or molecules can be 
incorporated and investigated by fluorescence,69 etc. The accessibility to only 
one side of the membrane limits the use of liposomes in electrochemical 
studies.  
The introduction of Solid-Supported bilayer lipid Membranes (SSMs) 70 
(Figure  5.3a) has represented an advancement in stability of membrane models. 
Thanks to the improved mechanical and long-term stability, combined with a 
more useful configuration, the SSM can be investigated by a variety of 
experimental techniques. 
Figure 5.3. A schematic illustration of SSM (a), polymer-supported psBLM 
(b), and tBLMs (c). 
An alternative strategy to improve some of the above-mentioned limitation of 
the original SSMs is represented by the development of hybrid SSMs. The lack 
of a well-defined ionic reservoir on the solid side of the bilayer represents an 
important drawback when studying membrane transport through ion carriers 
and channels. 71  This model system is characterized by a first monolayer 
(commonly an alkanylthiol monolayer) covalently attached to a metal substrate, 
on which a lipid monolayer is deposited either by transfer from air–water 
                                                     
68 Bangham, A.D., Standish, M.M., Watkins, J.C. J. Mol. Biol. 1965, 13, 238-252.  
69 Gatto, E.; Mazzuca, C.; Stella, L.; Venanzi, L.; Toniolo, C.; Pispisa, B. J. Phys. 
Chem. B, 2006, 110 (45), 22813-22818. 
70 Sackmann, E. Science 1996, 271, 43–48 
71 Raguse, B., Braach-Maksvytis, V., Cornell, B.A., King, L.G., Osman, P.D.J., Pace, 
R.J., Wieczorek, L. Langmuir 1998, 14, 648-659. 
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interface or through vesicle unrolling. However, stiffness of alkanylthiol/lipid 
SSMs is much higher than that of fluid biological membranes. In addition, the 
structure of thiol-based SSMs prevents formation of a water layer between the 
bilayer and the metal support. Therefore, such mixed SSMs are unsuitable for 
incorporation of integral proteins and for studies of ion transport through 
ionophores.  
In conclusion, SSMs are more stable in aqueous solution than their 
unsupported counterparts. Nevertheless, the proximity of the solid support may 
lead to decreased bilayer fluidity and represents a problem particularly for 
incorporation of transmembrane proteins. 
To avoid this problem it is possible to separate the membrane from the solid 
substrate using soft polymeric materials that are attached on the substrate and 
support the membrane. This approach, the so-called polymer-supported 
Bilayer Lipid Membranes (psBLM) (Figure  5.3b), has significantly reduced 
the frictional coupling between membrane-incorporated proteins and the solid 
support, and hence the risk of protein denaturation.70,72,73 
Another recent significant advance is represented by tethered Bilayers Lipid 
Membranes (tBLMs) (Figure 5.3c). The tethered system is composed of a first 
monolayer covalently attached to the solid surface and a second monolayer of 
free lipids. One of the most interesting properties of tBLMs is their high 
mechanical stability which provides a long and stable functionality 74 . 
Moreover metal supported tBLMs are characterized by a hydrophilic region 
interposed between the bilayer and the metal, which can accumulate small and 
medium molecules that pass across the membrane mimicking the biological 
system. These properties are due to a hydrophilic molecule terminating at one 
end with a disulfide group that anchors this ‘‘hydrophilic spacer’’ to the 
                                                     
72 Sackmann, E., Tanaka, M. Trends Biotechnol. 2000, 18, 58–64. 
73  Knoll, W., Frank, C.W., Heibel, C., Naumann, R., Offenhäuser, A., Rühe, J., 
Schmidt, E.K., Shen, W.W., Sinner A. Rev. Mol. Biotechnol. 2000, 74, 137–158. 
74 Vockenroth et al. BBA Biomembranes, 2007, 1768, 1114-1120. 
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surface of the metal. The other end of the hydrophilic spacer may be 
covalently linked to the polar head of a phospholipid molecule, giving rise to a 
supramolecule termed ‘‘thiolipid’’. The tethered lipid bilayer is characterized 
by mechanical stability and fluidity. Moreover, this system allows the 
incorporation of many different proteins. 
In conclusion, different biomimetic models have been so far developed 
opening new perspectives in the field of medical diagnostics, drug screening, 
and environmental control. Up to now, biomimetic membranes are not ready to 
incorporate integral proteins of high molecular weight, but incorporation of 
small proteins or fragments from epitopes have been widely demonstrated. 
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6. Role of β-turn structures in membrane permeability 
Nowadays, recurrent structural and functional activity in a membrane 
environment has been evaluated for peptides of diverse composition. Although 
hundreds of peptides interacting with membranes have now been characterized, 
these peptides have been classified into few conformational paradigms. In fact, 
strong relationship between conformation governing peptide structure and 
membrane activity among peptides have been previously defined.75 
β-Turn and β-sheet peptide conformations represent a highly diverse group of 
molecules at the level of primary structure. Despite such primary sequence 
differences, peptides presenting a common β-turn motif and interacting with a 
membrane share common features, with distinct hydrophilic and hydrophobic 
surfaces. Less is known about structures adopted by tryptophan-rich peptides. 
Trp residue possesses some crucial chemical properties. In fact it has a distinct 
preference for the interfacial region of lipid bilayers. In combination with Arg, 
participates in cation-π interactions, thereby facilitating enhanced peptide-
membrane interactions. Trp side-chains are also implicated in peptide and 
protein folding in aqueous solution, where they contribute by maintaining 
native and non native hydrophobic contacts. Moreover, they lead to structures 
for membrane-mimetic bound peptides that go far beyond regular α-helices 
and β-sheet structures.76 Synthetic peptides with defined secondary structure 
scaffolds, namely hairpins and helices, containing tryptophan residues, have 
been investigated to probe the influence of a large number of aromatic amino 
acids on backbone conformations. Several examples of prototypic β−structures 
conformations have been previously reported and studied. Moreover, it has 
been reported that membrane interaction could stabilize β-hairpin structures. 77 
                                                     
75 Yeaman, Y.; Yount, N. Pharmacologycal Reviews, 2008, 55(1), 27-54. 
76 Chan, D.I.; Prenner,E.J.; Vogel, H.J. B.B.A.. Biomembranes (2006),. 1758 (9), 1184-1202 
77 Rotondi, K.; Gierasch, L. Biopoplymers, 2004, 71(6), 638-651. 
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6.1 CSF114(Glc) a β-turn structure-based designed 
glycopeptide 
The glycopeptide CSF114(Glc) is characterized by the same amino acid 
composition, but in a different primary sequence of the myelin 
oligodendrocyte glycoprotein (MOG) peptide fragment 
[Asn31(Glc)]hMOG(30-50). CSF114(Glc) was potentially endowed with 
divergent conformational behavior, intended to optimally expose the glucosyl 
structure in the solid-phase conditions of and ELISA plate. Such optimal 
exposition could be obtained positioning the Asn residue at the tip of the 
specific CSF114(Glc) β-hairpin structure definitely designed with hMOG(30-
50) peptide amino acids. In particular, it is well known that the Asn-Gly 
sequence is the best choice in a type I’ β-turn structure. To stabilize the hairpin 
structure, the two putative turn residues were positioned in an almost central 
position in the primary sequence of the peptide, and the flanking residues were 
selected to optimize cross strand tertiary interactions. In particular, Glu-5 and 
Ser-6 side chains can interact throughout hydrogen bond formations, while 
Val-4 and Val-11 undergo hydrophobic interaction. 
 
A:    KN(Glc)ATGMEVGWYRPPFSRVVHL 
B:    TPRVERN(Glc)GHSVFLAPYGWMVK 
Figure  6.1. Amino acids primary sequence of (A) Asn31(Glc)]hMOG(30-50) 
and (B) CSF114(Glc) . 
The conformational properties of CSF114(Glc) in solution were investigated 
by NMR spectroscopy. Conformational studies based on mono and bi-
dimensional NMR experiments in HFA/H2O (1:1 v/v) showed that 
CSF144(Glc) contains a β-hairpin motif between residues 2 and 14 with a type 
I’ β-turn, with Asn7 and Gly8 as central residues.23 
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7. Mimetic antigens in a membrane model 
environment  
The glycopeptide CSF114(Glc), possibly mimicking neoepitopes from myelin 
proteins, has been studied in a membrane environment. Moreover, a small 
library of peptide analogues of CSF114(Glc) has been also synthesized and 
studied in the biomimetic membrane system. To further confirm the 
importance of the secondary structure of CSF114(Glc) peptide antigen we also 
synthesized the corresponding peptide characterised by the scrambled 
sequence Scramble CSF114(Glc) (VI) (see Table 7.1). In this random 
sequence containing the same amino acids of CSF114(Glc) (I) only the 
glucosylated Asn7 residue was left at its initial position in the sequence. 
Circular Dichroism studies of the scrambles sequence VI indicated a high 
tendency to the helix formation, and NMR analysis confirmed this indication. 
Several NMR parameters indicate the presence of a α-helix along residues 4-
15. Calculated structures (Figure 7.1) showed the expected helical segment. 
 
Figure  7.1. (a) Superposition of the 10 lowest energy conformers of 6. 
Structures were superimposed using the backbone heavy atoms of residues 3-
15 (thicker lines). Heavy atoms are shown with different colours (carbon, 
green; nitrogen, blue; oxygen, red; sulphur, gold). Side chains and hydrogen 
atoms are not shown for clarity. (b) Lowest energy conformer of 6. Asn7(Glc) 
and residues Lys3, Val4, Phe8, and Met10 are shown as Van der Waals surfaces. 
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Table  7.1 Peptide and glucopeptide sequences studied in 
biomimetic membranes 
Peptide Sequence 
CSF114(Glc) (I) TPRVERN(Glc)GHSVFLAPYGWMVK 
CSF114 (I’) TPRVERNGHSVFLAPYGWMVK 
Scramble CSF114(Glc) (VI) LAKVSYN(Glc)FRMETRVGWHPVGP 
Scramble CSF114 (VI’) LAKVSYNFRMETRVGWHPVGP 
 
7.1 The tethered Bilayer Lipid Membrane (tBLM) 
system 
We used tBLMs supported by a hanging-drop mercury electrode as an 
experimental model, as well as vesicles to be used in fluorescence experiments. 
With respect to gold, mercury has the advantage of providing a defect-free and 
fluid surface to the self-assembling spacer. 
The thiolipid used as linker in the tBLM was DPTL, 2,3-di-O-phytanyl-sn-
glycerol-1-tetraethylene glycol-D,L-α-lipoic ester (Figure  7.1.1). DPTL is 
composed of three distinct parts: a lipid head, a hydrophilic spacer, and an 
anchor group. 
 
Figure  7.1.1. The DPTL structure. 
The lipid residue facilitates to form the proximal lipid monolayer according to 
Van der Waals interactions between the hydrocarbon tails. The ion reservoir is 
represented by four ethylene glycol units and the anchor group provides 
stability of the proximal layer of the membrane through the covalent bond of 
the thiol group with mercury. Lipoic acid fragment provides a disulfide bridge, 
which is more stable than a simple thiol bond. 
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Subsequent immersion of the DPTL monolayer covalently linked to the 
mercury electrode, across a lipid film of DphyPC (Di-phytanoyl Phosphatidyl 
Choline) previously spread on the surface of the electrolyte solution, let obtain 
a lipid bilayer interposed between the hydrophilic moiety of the thiolipid and 
the aqueous solution. 
 
Figure 7.1.2. Representation of the different sub-structural elements of the 
tBLM, an Hg-supported DPTL/DphyPC film bathed by aqueous 0.1 M KCl. 
The electrical properties of a tBLM have been analyzed by AC Voltammetry 
and Electrochemical Impedance Spectroscopy (EIS). Fitting EIS data to a 
simple equivalent circuit (consisting of a RC mesh, which simulates the whole 
film, with in series the resistance of the aqueous electrolyte) it was possible to 
obtain the capacitance and resistance, which were fully compatible with 
formation of a tBLM starting from a DPTL monolayer.78 In this way, substrate 
has been identified as an accurate bilayer formation. 
                                                     
78 Wiegand, G.; Arribas-Layton, N; Hillebrand, H; Sackman, E; Wagner, P. J. Phys. 
Chem. B, 2002, 106, 4245. 
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7.2 Behaviour of glucosylated peptides CSF114(Glc) (I) 
and Scramble CSF114(Glc) (VI) in biomimetic 
membrane 
To further characterise the glucosylated peptide antigen CSF114(Glc) (I) in a 
membrane environment, we decided to study in parallel the random coil 
glucosylated peptide structure Scramble CSF114(Glc) (VI).26  
We incorporated CSF114(Glc) and Scramble CSF114(Glc) into different 
tBLMs and both glycopeptides were added indipendently into the electrolyte 
solution in a cell.  
In Figure  7.2 we can observe the in-phase component versus the applied 
potential E. The applied potential is gradually shifted toward more negative 
values, and the electric field within the hydrophilic spacer decreases in 
magnitude giving rise to a bell-shaped curve. The conductance of membrane-
containing glycopeptides shows a very steep rise in the proximity of -0.900 
V/SCE, followed by a rapid decrease probably due to the saturation of the 
hydrophilic region by the supporting cation K+, thus increasing tBLM 
permeability. 
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Figure  7.2. Plot of the in-phase component, Y’, of Hg-supported 
DPTL/DphyPC film bathed by aqueous 0.1 M KCl against the applied 
potential E, both in the absence (▲) and in the presence of CSF114(Glc) (●) 
or Scramble CSF114(Glc) (■). Freq = 10 Hz. 
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Permeability of membranes containing each glucopeptide could be due to the 
hydroxyl functions of glucose moiety linked to Asn at position 7. The use of 
elevated negative potentials (-0.900 mV) probably induce variations in the 
dipole of the hydroxyl groups. These electric changes in the glucosyl moiety 
could orient glucopeptides near the working electrode disrupting the 
membrane in the polar heads region. 
7.3 Behaviour of unglucosylated peptides CSF114 (I’) 
and Scramble CSF114 (VI’) in biomimetic 
membrane 
We synthesized the unglucosylated peptide sequences CSF114 (I’) and 
Scramble CSF114 (VI’) to be studied in the membrane model tBLM. Figure 
7.3.1 shows the conductance of a Hg-supported DPTL/DPhyPC film 
incorporating CSF114 and Scramble CSF114 against the applied potential E, 
as measured by the in-phase component Y’, of the electrode admittance at 10 
Hz. 
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Figure 7.3.1. Plot of the in-phase component, Y’, of Hg-supported 
DPTL/DphyPC film bathed by aqueous 0.1 M KCl against the applied 
potential E, both in the absence (▲) and in the presence of CSF114 (●) or 
Scramble CSF114 (■). 
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The results obtained for the CSF114-containing membrane were similar to 
those reported for a membrane containing Gramicidin D, a voltage-dependent 
well-known peptide forming ion channels in a membrane environment. 79 
Moreover, the presence of Scramble CSF114 (VI’) did not disrupt membrane 
properties. These results prompted us to perform a more detailed study.  
Plotting the real part against the imaginary part of impedance gives a Nyquist 
plot. The advantage of a Nyquist plot is that it gives a rapid data overview and 
allows qualitative interpretation. When plotting data in the Nyquist format is 
performed, the real axis should be equal to the imaginary axis so the shape of 
the curve should not be distorted. The shape of the curve is important for a 
qualitative interpretation of the data. The disadvantage of the Nyquist plot is 
that the frequency dimension of the data cannot be obtained.  
Figure 7.3.2 shows a variant of Nyquist plot, ωZ’ vs –ωZ’’, were Z’ and Z’’ 
are the in-phase and quadrature components of the impedance and ω is the 
angular frequency. 
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Figure 7.3.2. Exchanged axis Nyquist plot of bilayer (black), bilayer+ 
Scramble CSF114 (blue), and bilayer + CSF114 (red). 
                                                     
79 Moncelli, M.R.; Beccuci, L.; Schiller, S.M. Bioelectrochemistry, 2004, 63, 161– 167. 
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Impedance data can be interpreted on the basis of equivalent circuit models. 
These models are built with well-known passive elements i.e.., resistors, 
capacitors, and inductors. These elements can be combined in series and in 
parallel to obtain complex equivalent circuits. A certain physical meaning is 
then assigned to the various elements of the equivalent circuit as described in 
Figure 7.3.3a. 
1/C
 
Figure 7.3.3a. Graphic representation of various elements of the equivalent 
circuit.  
In the case of a bilayer, an isolated RC mesh, consisting of a resistance R and a 
capacity C in parallel, is represented by a semicircle whose diameter is equal 
to the reciprocal of the capacity of the mesh and whose maximum lies at an 
angular frequency equal to the reciprocal of the time constant RC of the mesh. 
EIS data were fitted to an equivalent circuit consisting of a low resistance of 
the aqueous solution in series with a RC mesh (Figure 7.3.3b). 
 
Rb 
Cb 
Rs 
 
Figure 7.3.3b. Schematic plot of the equivalent circuit used as a model for the 
bilayer. 
When the peptides were incorporated into the bilayer, EIS data were fitted to 
an equivalent circuit consisting of the circuit for the bilayer with an additional 
semicircle (Figure 7.3.4). 
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Figure 7.3.4. Schematic plot of the equivalent circuit used a model for the 
bilayer incorporating peptides. 
Fitting values are reported in Table 7.3.1. 
 
Table 7.3.1. Fitting values obtained for the bilayer and the 
bilayer incorporating unglycosylated peptides. 
 bilayer Bilayer+CSF114 Bilayer+Scramble CSF114 
Rs 
(Ω·cm2) 3.098 3.549 3.005 
Cb 
(μF/cm2) 0.937 1.501 1.222 
Rb 
(kΩ·cm2) 247 3.715 202 
Cp 
(μF/cm2) - 7.535 2.514 
Rp 
(kΩ·cm2) - 785 62.5 
 
We can observe an increase in membrane capacitance and a decrease in 
membrane resistance in the presence of CSF114 (I’). The decrease in 
membrane resistance of three orders of magnitude, which may be due to ionic 
currents through possible pores, is therefore much higher in CSF114-
incorporating membrane. The increase in membrane capacitance, which is 
related to the charge separation across the membrane, indicates a much more 
fluid and less densely packed membrane. The presence of a poorly packed 
bilayer in the presence of the unglycosylated peptide β-turn structure CSF114 
is evident. However, the capacitance remains below 2.4 μF cm-2, indicating the 
integrity of the membrane. On the other hand, the presence of random coil 
Scramble CSF114 (VI’) did not disrupt the membrane. 
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These results let us to hypothesize that a β-turn peptide structure is crucial for 
interaction with the bilayer. 
7.3.1 Charge through the membrane in the particular case of the β-
turn structure CSF114 (I’) 
Charge Q versus time t has been recorded on a tBLM incorporating 4μM 
CSF114 immersed in aqueous 0.1 M KCl, performing a potential step from  
–0.300 V to –1.00V. After an initial abrupt increase in charge, due to the flow 
of the capacitive current required charging the tBLM, the curve assumes a 
sigmoidal shape tending to a constant limiting value (Figure 7.3.5). 
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Figure 7.3.5. Charge versus time curve of a tBLM in 0.1 M KCl incorporating 
CSF114 4 μM following a potential step from –0.300 V to –1.0V with 100 mV 
decrements. 
It was previously reported the relationship between the charge through the 
bilayer and a nucleation-and-growth mechanism of the peptide into the 
membrane.80 The absence of changes in the curve of the charge Q as we 
proceed toward more negative potentials strongly suggests that the interaction 
                                                     
80 Beccuci, L.; Moncelli, M.R.; Naumann, R.; Guidelli, R. J. Am. Chem. Soc. 2005, 
127, 13316-13323.  
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with the β-turn peptide CSF114 (I’) proceeded without a nucleation-and-
growth mechanism. 
7.3.2 Fluorescence studies of the β-turn structure CSF114 
incorporated in liposomes 
Tryptophan fluorescence is widely used as a tool to monitor changes in 
proteins conformation. Thanks to the presence of Trp in CSF114 sequence, 
fluorescence studies in liposomes were performed in collaboration with Prof. 
M. Venanzi at the University of Rome “Tor Vergata” (Dipartimento di Scienze 
e Tecnologie Chimiche).  
To shed further light on results obtained in tBLM environment, membrane-
perturbing activity of the β-turn structure CSF114 was investigated by 
fluorescence studies. The peptide-liposome interaction was measured by 
incubating 4 μM CSF114 (I’) with PC/PG liposomes (2:1) at different 
concentrations (0-300 μM). The fluorescence of Trp residue was measured at 
an excitation wavelength of 280 nm and an emission wavelength between 320 
and 420 nm. 
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Figure 7.3.6. Plot of the fluorescence intensity of the β-turn structure CSF114 
(I’) incorporated in liposomes at different concentrations. 
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All Trp-emission spectra recorded at different liposome concentrations were 
identical (Figure 7.3.6) suggesting that liposomes did not perturb the overall β-
turn conformation of the peptide. The extrinsic fluorescence intensity of Trp 
residue was modified to a minor extent, if any, by the membrane environment. 
Analogous results were observed at higher peptide concentration (data not 
shown). If the Trp residue is not involved in the peptide-membrane- 
interaction, the possibility of fluorescence intensity changes are less likely 
because its position 18 near the C-terminus in CSF114-peptide sequence. 
For this reason, we decided to undertake anisotropy experiments. Anisotropy 
allows studying changes in the emission dipole during the excited state 
lifetime, measuring the relative orientation between the absorption and 
emission dipoles. Molecules are free to rotate and randomly oriented in 
solution, so the direction of the transition dipoles is randomized. If vesicles-
peptide interactions occur, the random disposition of the peptide could change, 
thus modifying its anisotropy.  
Anisotropy of both isolated vesicles and CSF114-containing vesicles were 
calculated using a polarization mode. The G-factor of the instrument was 
previously calculated (1,566332). Anisotropy of a solution containing 10 μM 
CSF114 was calculated in the absence and in the presence of liposomes (300 
μM). Results are reported in Table 7.3.2. 
Table 7.3.2. Anisotropy values obtained for Trp residue.  
 Anisotropy
CSF114 0.0212 
CSF114 + liposomes 0.0176 
 
The absence of Trp anisotropy variation suggests that both the position and 
orientation of Trp residue in the peptide are not involved in the membrane 
disruption, even though the peptide can be moved to different positions around 
the liposomes. 
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7.3.3 Electrochemical study of different β-turn peptide structure 
MBH36 and TrpZip 
Different unglycosylated peptide β-turn structures have been selected from the 
literature to study their behaviour in biomimetic membranes. In particular, 
starting from observations previously reported by Perez-Paya et al., 81  we 
selected MBH36 possessing high population of type I’ β-hairpin structure in 
solution (as demonstrated by detailed CD and NMR analysis) and a sequence 
rich in Trp residues (TrpZip) containing a structural motif, the Tryptophan 
zipper, greatly stabilizing the β-hairpin conformation, even in short peptides 
consisting of only 12 amino acid residues. The peptide TrpZip is monomeric 
and folds cooperatively in water and the NMR structure analysis reveals 
exceptionally a well-defined β-hairpin conformation stabilized by cross-strand 
pairs of indole rings.82 
Peptide sequences reported in Table 7.3 have been studied in the membrane 
model system tBLM.  
 
Table 7.3 Peptide sequences studied in biomimetic membranes 
Peptide Sequence 
MBH36 (VII) RGKYTYNGITYEGR 
TrpZip (VIII) SWTWENGKWTWK 
 
Both β-hairpin peptide structures characterised by different primary sequences, 
MBH36 (VII) and TrpZip (VIII), were studied in a membrane environment 
(Figure 7.3.7). Peptide MBH36 did not disrupt the mimetic membrane and 
TrpZip presented a small interaction (two orders below CSF114 (I’) 
interaction value).  
                                                     
81 Pastor, M. T.; de la Paz, M. L.; Lacroix, E.; Serrano, L.; Perez-Paya, E. Proc. Natl. 
Acad. Sci. 2002, 99, 614-619. 
82 Cochran, A.G.; Skelton, N.J.; Starovasnik, M.A. Proc. Natl. Acad. Sci. 2001, 98, 
5578-5583. 
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Figure 7.3.7. Plot of the in-phase component, Y’, of a Hg-supported 
DPTL/DphyPC film bathed by aqueous 0.1 M KCl against the applied 
potential E, both in the absence (▲) and in the presence of MBH36 (●) or 
TrpZip (■) 
Several aspects of peptide structures relevant to membrane activity have to be 
considered. In particular, structural parameters such as conformation, charge, 
hydrophobicity, amphipathicity, and polar angle could be correlated with the 
membrane activity (Figure 7.3.8). 
 
Figure 7.3.8. Inter-relationship among structural determinants in peptides: 
amino acid sequence influences charge (Q), amphipathicity (A), and/or 
hydrophobicity (H), but also governs polar angles (θ) 
 and/or conformation (χ). 
It is important to note that these molecular determinants are interdependent, 
and therefore, modification of one parameter often leads to compensatory 
effects in others.  
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Even if CSF114 (I’) and Scramble CSF114 (VI’) have the same amino acid-
composition (but different primary sequence), their membrane activity. In this 
case, differences in their peptide structure (β-turn versus random coil) results 
in different activity in a membrane environment. 
In the particular case of TrpZip, the peptide presents small activity probably 
due to the Trp rich sequence.83  
Therefore, changes in composition, sequence, and intramolecular bonds may 
profoundly affect the structure-activity relationships of peptides in solution, 
upon binding to target membranes. Moreover, these features may be specific 
for distinct peptides as they interact with specific pathogens or in specific 
physiologic microenvironments. Therefore, all the parameters described above 
can be related to membrane-peptide interactions. 
                                                     
83 Yeaman, M.R.; Yount, N.Y. Pharmacological Reviews, 2003, 55, 27-55.  
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Experimental Part 
8. Experimental Part A 
8.1 Materials and methods 
The chemicals were purchased from Sigma-Aldrich and used without further 
purification. Peptide-synthesis grade N,N-dimethylformamide (DMF) was 
from Scharlau (Barcelona, Spain). HPLC-grade MeCN was purchased from 
Carlo Erba (Italy). Dry solvent DCM was distilled immediately before use 
over CaH2 under nitrogen. Protected amino acids and resins were obtained 
from Calbiochem-Novabiochem AG (Laufelfingen, Switzerland). HATU, 
TBTU and HOBt were purchased from Advanced Biotech Italia (Milano, 
Italy). Activation products that contain triazine were obtained from EspiKem 
(Firenze). 
TLC were carried out on silica gel precoated plates (Merck; 60 Å F254) and 
spots located with: (a) UV light (254 and 366 nm), (b) ninhydrin (solution in 
acetone), (c) Cl2/toluidine, (d) Fluram® (Fluka; fluorescamine, 4-phenyl-
spyro[furan-2(3H),1’-isobenzofuran]-3,3’-dione) in acetone, (f) a basic 
solution of permanganate [KMnO4 (3 g), K2CO3 (20 g), and NaOH (0.25 g) in 
water (300 ml)], (g) 10% H2SO4 in EtOH. Flash Column Chromatography 
(FCC) was performed on Merck silica gel 60 (230-400 mesh) according to 
Still et al84. 
1H and 13C NMR spectra were recorded at 400 and 100 MHz, and 200 and 50 
MHz respectively, on a Varian spectrometer in deuterated solutions and are 
reported in parts per million (ppm), with solvent resonance used as reference. 
Chemical shifts (δ) are reported in ppm relative to TMS and coupling 
constants (J) are reported in Hz. The multiplicity were marked as s =singlet, d 
                                                     
84 W.C. Still, M. Khan, A. Mitra, J. Org. Chem., 1985, 50, 2394-2395. 
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= dublet, t = triplet, q = quartet, m = multiplet. Intensities of signals were 
estimated as vs = very strong, s = strong, m =medium, w = weak), b = broad. 
Semi-preparative purification via HPLC were performed by a Phenomenex 
Jupiter C18 (250 × 4.6 mm) colum at 28 °C using using an Waters instrument 
(Sepation Module 2695, detector diode array 2996) or using a Beckman 
System Gold Nouveau apparatus equipped with a diode array detector. 
Analytical HPLC were performed by a Waters instrument (2996 Alliance) 
using a Phenomenex Jupiter column 5m C18 300Å (250 × 4.6 mm). The 
solvent systems used were: A (0.1% TFA in H2O) and B (0.1 % TFA in 
CH3CN). The flow rates were 1 mL/min for analytical HPLC and 4 mL/min 
for semi-preparative HPLC, with the indicated linear gradients. Products were 
characterized by ACQUITY UPLC (Waters Corporation, Milford, 
Massachusets) coupled to a single quadrupole ESI-MS (Micromass ZQ) using 
a 2.1 x 50 mm 1.7 μm ACQUITY BEH C18 at 30 °C, with a flow rate of 
0.45mL/min. The products were lyophilized with an Edwards apparatus, 
model Modulyo. 
Cyanogen-bromide activated resin (CNBr-sepharose) used for the affinity 
column and bovine serum albumin (BSA) used for the quantification of the 
isolated antibody fractions were purchased from Sigma-Aldrich (Milan, Italy). 
The solutions used for the affinity chromatography were: Hydrochloric acid (1 
mM), coupling buffer (0.1 M, NaHCO3, NaCl, 0.5 M), glycine solution (0.2 M, 
pH 8.0), acetate buffer (0.1 M, pH 4.3, 0.5 M NaCl), phosphate buffer saline 
(PBS) (0.1 M, pH 7.0), glycine solution (0.1 M pH 2.6). NaHCO3 buffer (0.1 
M, pH 8.3). All reagents were obtained from Merck (Darmstadt, Germany). 
8.2 Synthesis of glucosyl amino acid derivatives. 
8.2.1 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl chloride (1) 
The commercially available 1,2,3,4,6-pentaacetate α-D-glucopyranose (12 
mmol) was dissolved in DCM (25 mL), then SOCl2 (10 eq.) and AcOH (3 mL) 
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O
AcO
AcO
OAc
N3
OAc
were added under nitrogen atmosphere. The mixture was allowed to react at 0 
ºC for 1 h and then left for 16 h at r.t. under strirring. The reaction was 
monitored by TLC [AcOEt/hexane (1:1), developed by vanilline]. After 
evaporation of the solvent under vacuum, coevaporation with toluene the crude 
was purified by cristallisation  from petroleum ether/ diethyl ether.  
(1) Yield 91%. Rf = 0.63 [AcOEt/hexane (1:1), 
vanilline]. 1H NMR (400 MHz, CDCl3): δ = 5.28 (d, 
1H, J1,2=8.2 Hz, H–1), 5.20–5.12 (m, 3H, J4,5=9.7 Hz, 
H–2, H–3, H–4), 4.24 (dd, 1H, J6a,6b=12.5 Hz, H–6a), 
4.15 (dd, 1H, H–6b), 3.80 (ddd, 1H, J5,6a=4.7 Hz, J5,6b=2.3 Hz, H–5), 2.08, 
2.06, 2.01, 1.99 (4s, 4 × 3H, 4 × Ac); 13C NMR (125 MHz, CDCl3): δ = 170.5, 
170.0, 169.2, 169.0 (4 × CO-Ac), 87.5 (C-1), 75.5 (C-5), 73.3 (C-3), 72.7 (C-
2), 67.5 (C-4), 61.5 (C-6), 20.6, 20.5, 20.4 (4 × CH3-Ac). Results are 
consistent with data previously reported .85.  
8.2.2 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl azide (2α) 
To a solution of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl chloride (1) (11.5 
mmol) in THF, TBAT (1.35 eq.) and TMS-N3 (1.35 eq.) were added. After 36 
h under reflux the reaction mixture was quenched. Crude was cristallized from 
EtOH obtaining the anomeric mixture 9:1 (α/β). The two anomers were 
successfully purified independently by FCC (AcOEt/Hexane, 1:1) and 
recristallized from EtOH. 
(2) Yield = 56%, Rf = 0.3 [DCM, vanilline], 1H NMR 
(200MHz, CDCl3) δ = 5.59 (d, J1,2=4.4 Hz, 1H, H-1), 5.33 
(t, J=10 Hz, 1H, H-2), 5,05 (d, J=9.4 Hz, 1H, H-3), 4.90-
5.00 (m, 2H, H-4 H-5), 4.29-4.10 (m, 2H, H-6 H-6’), 
2.09-2.01 (m, 12H, 4xOAc). Results are in agreement with data previously 
reported.86. 
                                                     
85 Ibatullin, F.M.; Stanislav, I.S. Tetrahedron letters, 2002, 43, 9577-9580. 
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8.2.3 3,4,6-Tri-O-acetyl-α-D-glucopyranosyl isoxazoline (3) 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide (2) (300 mg, 0.804 mmol) 
and Ph3P (210 mg, 0.804 mmol) were dissolved in 1,2- dichloroethane (8 mL) 
in the presence of 4Å molecular sieves under Argon in a sealed vessel. The 
resulting solution was heated at 130ºC under microwave conditions at 100W 
for 10 minutes. Then the reaction mixture was cooled to room temperature and 
concentrated under vacuum. Compound 3 was purified by FCC 
(hexane/AcOEt/Et3N, 1:3:1%) obtaining pure isoxazoline 3 (137 mg, 52%) as 
a colourless oil. Rf= 0.23 (hexane/AcOEt, 1:3, vanilline);  
1H NMR (400 MHz, CDCl3) δ = 2.01 (s, 3H, OAc), 
2.04 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.09 (s, 3H, 
OAc), 3.62 (ddd, J = 8.8, 5.2, 2.4, 1H, H-5), 4.11 (dd, 
J = 12.6, 2.8, 1H, H-6), 4.23 (dd, J = 12.4, 5.2, 1H, 
H-6'), 4.37 (dd, J = 7.0, 4.0, 1H, H-2), 4.88 (dd, J = 
8.6, 4.2, 1H, H-4), 5.13 (t, J = 4.2, 1H, H-3), 5.81 (d, J = 7.4, 1H, H-1) ppm; 
13C NMR (100 MHz, CDCl3) δ = 14.3, 20.7, 20.8, 20.8, 63.2, 67.3, 67.7, 70.7, 
75.9, 92.7, 168.4, 169.2, 169.5, 170.3 ppm; ESI-MS: m/z calcd for C14H20O8N 
(M + H)+=330.12, found 330.12. Results are consistent with previously 
reported data.87. 
8.2.4 Fmoc-Asp(OtBu)-Opfp (4a) 
Pentafluorophenol (4 mmol) was added dropwise to a solution of Fmoc-L-
Asp(OtBu)-OH (1 equiv) in dioxane (12 mL) and then DCC (1 equiv) was 
added at 0 °C. The mixture was stirred 2 h at r.t. and checked by TLC Rf = 
0.53 [DCM/MeOH, 13:1; KMnO4]. After filtration, the solution was 
concentrated. Crude oil was re-crystallized from hexane obtaining the desired 
product as a white powder. 
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Yield = 97%, 1H MNR (200 MHz, DMSO) δ = 7.74 (d, 2H, 
4-H 5-H Fmoc), 7.57 (d, 2H 1-H 8-H Fmoc), 7.32 (m, 4H, 
Fmoc), 5.96 (d, 1H, J=9.2 Hz, NH), 5.10-4.95 (m, 1H, Hα), 
4.23-4.54 (m, 3H, CH2 CH Fmoc), 3.03 (2H, ABMX system, 
JAB=17.6 Hz, JAM=4.9 Hz, JBM=4.7 Hz), 1.46 (s, 9H, tBu). 13C-NMR (DMSO) 
δ(ppm): 169.76 (COOPfp), 166.7 (COOtBu), 155.94 (OCONH), 82.70 
(OCCH3 tBu), 67.49 (CH2 Fmoc), 50.24 (α-CH), 47.02 (CH Fmoc), 37.56 
(β−CH2), 27.91 (3 CH3 tBu). IR (KBr) ν(cm−1): 3367 (NH), 3080 (CH 
aromathic), 2980-2855 (CH alifatic), 1798 (C=O pentafluorophenilester); 1725 
(C=O ester Asp), 1706 (C=O uretane Fmoc), 1515 (C=C aromatico).  
8.2.5 Fmoc-Asp(Cl)-OPfp (4) 
Fmoc-Asp(OtBu)-OPfp 4a (3.8 mmol) was treated with TFA (3 ml). After 30 
min SOCl2 was added to the reaction mixture (100 eq.), which was left under 
stirring by one day at r.t. Reaction was monitored by 1H NMR. Solvent was 
co-evaporated with THF to obtain compound 4 as a white solid.  
1H-NMR (CDCl3) δ(ppm): 7.75 (2 H, d, 4-H and 5-H Fmoc), 
7.56 (2 H, d, 1-H e 8-H Fmoc), 7.31 (4 H, m, 2-H, 7-H, 3-H 
and 6-H Fmoc), 5.70 (1 H, d, N-H, J=8.4 Hz), 4.98 (1H, m, 
2-H), 4.50 (2 H, d, CH2 Fmoc, J=6.6 Hz), 4.25(1H, t, CH 
Fmoc, J=6.6 Hz), 3.69 (2 H, ABMX system, 3-H2, JAB=19 Hz, JAM=5.1 Hz, 
JBM=4.8 Hz). 13C-NMR (CDCl3) δ(ppm): 172.27 (COCl), 143.36 (COOPfp), 
141.35 (OCONH), 67.64 (CH2 Fmoc), 50.36 (α-CH), 48.62 (β-CH2), 47.03 
(CH Fmoc). IR (KBr) ν(cm−1): 3322 (NH), 3072 (CH aromatic), 2951 (CH 
aliphatic), 1788 (C=O pentafluorophenilester), 1740 (C=O Asp-Cl);1699 
(C=O uretane Fmoc); 1519 (C=C aromatico), 739 (C-Cl).  
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8.2.6 Modification on the side chain of the aspartic acid with a 
thiopyridine moiety  
General procedure: Oxalyl chloride (1.1 eq.) was added dropwise to a stirred 
solution of comercially available Fmoc-Asp(OH)-OtBu (2.43 mmol) or Z-
Asp(OH)-OtBu (0.55 mmol) at 0ºC under N2. The reaction mixture was stirred 
at 0 ºC for 1 h and then warmed to r. t. over 2 h. The crude chloride compound 
was taken up in DCM and then added to a solution of thiopyridine (1 eq.) and 
triethylamine (1 eq.) in DCM at 0 ºC. After stirring for 30 min, the mixture 
was poured into ice-cold water. The organic phase was separated and washed 
with ice-chilled KOH solution (5%), and water. The organic phase was 
separated, dried over Na2SO4, filtered, and concentrated under reduced 
pressure, to give the desired compound in quantitative yield. This material was 
used immediately without further purification.  
Z-Asp(Spy)-OBzl (6): 1H NMR (200 MHz, CDCl3) δ =3.32- 3.39 (m, 2H, 
CH2 Asp), (m, 1H, CH Asp), 5.05-5,16 (m, 4H, CH2 Z, CH2 
Bzl), 5.79 (d, 1H, J=7.4 Hz, NH), 729 (m, 14H, Ar Bzl, Ar 
Z, Ar Py). 
 
Fmoc-Asp(SPy)-OtBu (7): 1H NMR (200 MHz, CDCl3) δ = 1.45 (s, 9H, tBu), 
2.68-2.96 (m, 2H, CH2 Asp), 4.23-4.52 (m, 5H, CH2 Fmoc, 
CH Fmoc, CH Asp), 5.8 (d, 1H, J=8.4 Hz, NH), 7.28-7.78 
(m, 12H, Fmoc, Py). ESI-MS: m/z calculated (M + 
H)+=505.60.12, found 505.30. 
8.2.7 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosylamine (8) 
To a solution of commercially available 2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl azide (10 mmol) in MeOH, we added 20% Pd(OH)2/C. The 
mixture was stirred for 24 h at r.t. under H2, checked by TLC [AcOEt/hexane, 
3:1; UV, fluorescamine, and vanilline], filtered over celite, washed with 
ZHN
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MeOH and concentrated. The desired compound 1 was re-crystallized from 
THF/hexane. 
2,3,4,6-tetra-O-acetyl-β-D-glucopyranosylamine (8), yield 98%. Rf = 0.37. 1H 
NMR (200 MHz, CDCl3) δ = 2.03 (s, 3H, OAc), 
2.04 (s, 6H, 2×OAc), 2.07 (s, 3H, OAc), 3.67-3.75 
(m, 1H, H-5), 4.03 (d, J = 12.2 Hz, 1H, H-6), 4.28 
(pd, J = 12.8 Hz, 1H, H-6’), 4.96 (t, J = 9.6 Hz, 1H, H-2), 5.12 (t, J = 10 Hz, 
1H, H-4), 5.27-5.36 (m, 2H, H-1 and H-3) ppm. 
8.2.8 Coupling reactions between modified aspartic acid and glucose 
General procedure via 3,4,6-tri-O-acetyl-α-D-glucopyranosyl isoxazoline 
intermediate:  
2,3,4,6-Tetra-O-acetyl-α or β-D-glucopyranosyl azide (0.72 mmol) and Ph3P (l 
eq.) was dissolved in 1,2-dichloroethane (6 mL) in the presence of 4Å 
molecular sieves. The resulting solution was heated at 130 ºC under 
microwave conditions at 100W for 10 minutes. Then the reaction mixture was 
cooled to r.t. and concentrated under vacuum. The activated amino acid and 
CuCl2·2H2O, , were added to the reaction mixture, which was heated at 30 ºC 
for 24 h. The reaction mixture was diluted with 100 mL Et2O and washed with 
2x100 mL H2O. The organic layer was dried over Na2SO4 and concentrated 
under vacuum to give the crude product, which was purified by FCC 
(hexane:EtOAc, 1:1). 
General procedure for microwave-assisted synthesis:  
Fmoc-L-Asp-OtBu (60 mg, 0.144 mmol), 2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl amine (3) (1 equiv), NMM (1 equiv), and DMT-NMM/BF488,89 
                                                     
88  [4-(4,6-dimethoxy-1,3,5-triazin-2-yl-)-4-methylmorpholinium tetrafluoroborate], 
“Process for the preparation of N-triazinylammonium salts”. Filing date 07/11/2005. 
Applicant: Italvelluti S.p.a. Inventors: Z. Kaminski, A. M. Papini, B. Kolesinska, J. 
Kolesinska, K. Jastrzabek, G. Sabatino, R. Bianchini. PCT/EP2005/055793 (2005). 
89 Z. J. Kamiński, B. Kolesińska, J. Kolesińska, G. Sabatino, M. Chelli, P. Rovero, M. 
Błaszczyk, M. L. Główka, A. M. Papini, J. Am. Chem. Soc., 2005, 127, 16912-16920. 
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(1 equiv) as coupling reagent were dissolved in acetonitrile (2 ml). The vessel 
was charged with the reaction mixture, sealed, and placed into the microwave 
synthesizer CEM EXPLORER 48® applying the reaction conditions reported 
in Table  1.1.3. The reaction tube was taken off after performing the coupling 
reaction. Then the mixture was transferred into a round bottom flask. The 
solvent was evaporated under reduced pressure, the residue was dissolved in 
CHCl3 and then washed with water, 0.5 M aqueous KHSO4, water, 0.5 M 
aqueous NaHCO3, and water again. Organic layer was dried over anhydrous 
Na2SO4, filtered off and concentrated to dryness. The two anomers were 
successfully separated by FCC (AcOEt/Hexane, 1:1). The two independent 
pure anomers were dried under vacuum over P2O5 and KOH till constant 
weight  
Z-L-Asn(αGlcAc4)-OBn (9α) The Asparagine derivative was prepared 
following the general coupling procedure via isoxazoline intermediate 
employing α-azide (300 mg, 0.85 mmol), Ph3P (1 equiv), Z-Asp(SPy)-OBn 
(1.5 equiv) as acylating reagent, and CuCl2· 2H2O (1.5 equiv).. After 
purification of the crude via FCC (hexane/AcOEt, 1:1) we obtained compound 
9α as a white solid (Rf = 0.30, hexane/AcOEt, 1:1).  
1H NMR (400 MHz, CDCl3) δ = 1.96 (s, 
3H), 2.00 (s, 3H), 2.02 (s, 3H), 2.04 (s, 3H), 
2.87 (dm, J = 16, 1H), 2.95 (dm, J = 16, 
1H), 3.84 (m, 1H), 3.97 (dd, J = 2, 8, 1H), 
4.24 (dd, J = 4, 8, 1H), 4.67 (m, 1H), 5.00-
5.20 (m, 6H), 5.25-2.30 (m, 1H), 5.80 (t, J = 6, 1H), 5.92 (s, 1H), 6.57 (m, 1H), 
7.30-7.35 (m, 10H); ESI-MS m/z calcd 686.2323, found 687.2305. 1H NMR 
Results were consistent with data previously reported by Zhang et al90. 
                                                     
90 Zhang, H.; Wang, Y.; Thürmer, R.; Parvez, K.; Atta-ur-Rahman, I. C.; Voelter, W. Z. 
Naturforsch., B: Chem. Sci. 1999, 54, 692-698. 
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Z-L-Asn(βGlcAc4)-OBn (9β) The Asparagine derivative was prepared 
following the general coupling procedure via isoxazoline intermediate 
employing β-azide (300 mg, 0.85 mmol), Ph3P (1 equiv), Z-Asp(SPy)-OBn 
(1.5 equiv) as acylating reagent, and CuCl2·2H2O (1.5 eq.)additive.. After 
purification of the residue by FCC (hexane/AcOEt, 1:1) we obtained 
compound 9β as a white solid (Rf = 0.2, hexane/AcOEt, 1:1).  
1H NMR (200MHz, CDCl3) δ= 7.29-
7.21 (m, 10H, 2Ph), 6.61 (d, 1H, J=9.1 
Hz, H-1), 5.96 (d, 1H, J=8.6 Hz, 
NHCOBn), 5.25-4.79 (m, 8H, H-1,2,3,4 
2 CH2Ph), 4.59-4.55 (m, 1H, CH), 4.24-3.91 (m, 2H, H-6,6’), 3.74-3.66 (m, 
1H, H-5), 2.85-2.59 (dd, 2H, J=16.3, J=4.3 Hz, COCH2CH), 1.98, 1.97, 
1.95,1.93 (4s, 12H, Ac). Results were consistent with data previously 
reported.90 
Fmoc-L-Asn(αGlcAc4)-OtBu (10α): The Asparagine derivative was prepared 
following the procedure for microwave-assisted synthesis. After purification of 
the crude by FCC (hexane/AcOEt, 1:1) we obtained compound 10α as a white 
solid. (Rf = 0.52, AcOEt/Hexane, 1:1, fluorescamine, vanilline); [α]D  = +13.21; 
ESI-MS: m/z calcd for C37H44O14N2 =740.28, found (M+H)+=741,45. 
1H NMR (400 MHz, CDCl3) δ = 1.46 (s, 9H, 
tBu), 2.01, 2.03 (2 s, 12H, 4×OAc), 2.87 
(system ABMX, JAB = 17.2 Hz, JAM = 4.8 
Hz, JBM = 4.4 Hz, 2 H, Asn-β-CH2), 3.80 
(dq, J = 4.0 Hz, J=2 Hz, 1H, H-5), 4.06 (pd, 
J = 11.6 Hz, 1H, H-6), 4.19 (t, J = 7.2 Hz, 1H, Fmoc-CH), 4.26 (dd, J = 12.8 
Hz, 4.4 Hz, 1H, H-6’), 4.32-4.44 (m, 2H, Fmoc-CH2), 4.51-4.55 (m, 1H, Asn-
α-CH), 5.09-5.15 (m, 2H, H-2 and H-4), 5.23 (t, J=9.6 Hz, 1H, H-3), 5.72 (m, 
2H, H-1 and Asn-α-NH) 7.28 (app-dt, 5H, 1-NH and Fmoc-Ar), 7.58 (app-d, 
2H, Fmoc-Ar), 7.74 (d, J = 7.2 Hz, 2H, Fmoc-Ar) ppm. 13C NMR (100 MHz, 
CDCl3) δ = 20.5, 20.5, 20.6 (C(O)CH3), 27.8 (C(CH3)), 36.7 (Cβ), 47.1(Fmoc 
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CH), 50.5 (Cα), 61.3 (C-6), 67.1 (Fmoc-CH2), 67.6, 70.1, 72.6, 72.7 (C-2,C-
3,C-4,C-5), 82.9 (C(CH3)3), 91.9 (C-1), 119.9, 125.0, 125.1, 127.0, 127.7, 
141.2, 143.7, 143.7 (Ar-C), 155.5, 169.0, 169.0, 169.3, 169.3, 170.0, 170.4 
(C=O). 
Fmoc-L-Asn(βGlcAc4)-OtBu (10β): The Asparagine derivative was prepared 
following the general procedure for microwave-assisted synthesis. After 
purification of the residue by FCC (hexane/AcOEt, 1:1) we obtained 10β as a 
white solid. (Rf = 0.30 [AcOEt:Hexane, 1:1,(fluorescamine, vanilline)]; 
[α]D=22.94; ESI-MS: m/z calcd for C37H44O14N2 =740.28, found 
(M+H)+=741,73;  
1H NMR (400 MHz, CDCl3) δ= 1.46 (s, 
9H, tBu), 1.99, 2.01 (2 s, 12H, 4×OAc), 
2.84 (system ABMX, JAB = 16.4 Hz, 
JAM = 4.4 Hz, JBM = 4.0 Hz, 2H, Asn-β-
CH2), 3.70 (pt, J = 4.8 Hz, 1H, H-5), 4.04 (d, J = 12.4 Hz, 1H, H-6), 4.19 (t, J 
= 7.2 Hz, 1H, Fmoc-CH), 4.23 (dd, J = 12.8 Hz, J = 4.4 Hz, 1H, H-6’), 4.31-
4.42 (m, 2H, Fmoc-CH2), 4.69-4.72 (m, 1H, Asn-α-CH), 4.98 (t, J = 9.6 Hz, 
1H, H-2), 5.10 (t, J = 10 Hz, 1H, H-4), 5.29-5.37 (m, 2H, H-1 and H-3), 6.09 
(d, J = 8.0 Hz, 1H, Asn-α-NH), 6.87 (d, J = 9.2 Hz, 1H, NH-1), 7.28 (app-t, 
2H, Fmoc-Ar), 7.37 (app-t, 2H, Fmoc-Ar), 7.57 (d, J = 7.2 Hz, 2H, Fmoc-Ar), 
7.73 (d, J = 7.2 Hz, 2H, Fmoc-Ar) ppm. 13C NMR (100 MHz, CDCl3) δ = 20.5, 
20.5, 20.6 (C(O)CH3), 27.8 (C(CH3)), 37.9 (Cβ), 47.1(Fmoc CH), 50.9 (Cα), 
61.5 (C-6), 67.1 (Fmoc-CH2), 68.0, 70.5, 72.6, 73.6 (C-2,C-3,C-4,C-5), 78.0 
(C-1), 82.4 (C(CH3)3), 119.9, 125.1, 125.1, 127.0, 127.6, 141.2, 143.7, 143.8 
(Ar-C), 156.1, 169.5, 169.7, 169.8, 170.5, 170.7, 171.0 (C=O). Results were 
consistent with the data previously reported91 
                                                     
91 Van Ameijde, J.; Albada, H.B.; Liskamp, R.; J. Chem. Soc. Perkin Trans. 1, 2002, 
1042-1049. 
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8.2.9 tert-Butyl deprotection of Fmoc-protected amino acids 
The pure t-Bu esters 10α and 10β were dissolved in TFA in DCM (1:1). The 
reaction mixture was stirred for 3 hours at r.t. The solvents were evaporated 
and after dissolution in water and freeze drying, Fmoc-protected glycosyl 
amino acids 11α and 11β were obtained. 
Fmoc-L-Asn(αGlcAc4)-OH (11α) yield 97%. Rf = 0.24 (AcOEt/Hexane, 2:1, 
UV and vanilline). 1H NMR (400 MHz, CDCl3) 
δ =  2.01, 2.03 (2 s, 12H, 4×OAc), 2.87 (system 
ABMX, JAB = 17.2 Hz, JAM = 4.8 Hz, JBM = 4.4 
Hz, 2 H, Asn-β-CH2), 3.80 (dq, J = 4.0 Hz, J=2 
Hz, 1H, H-5), 4.06 (pd, J = 11.6 Hz, 1H, H-6), 
4.19 (t, J = 7.2 Hz, 1H, Fmoc-CH), 4.26 (dd, J = 12.8 Hz, 4.4 Hz, 1H, H-6’), 
4.32-4.44 (m, 2H, Fmoc-CH2), 4.51-4.55 (m, 1H, Asn-α-CH), 5.09-5.15 (m, 
2H, H-2 and H-4), 5.23 (t, J=9.6 Hz, 1H, H-3), 5.72 (m, 2H, H-1 and Asn-α-
NH) 7.28 (app-dt, 5H, 1-NH and Fmoc-Ar), 7.58 (app-d, 2H, Fmoc-Ar), 7.74 
(d, J = 7.2 Hz, 2H, Fmoc-Ar) ppm. 13C NMR (100 MHz, CDCl3) δ = 20.5, 20.5, 
20.6 (C(O)CH3), 36.7 (Cβ), 47.1(Fmoc CH), 50.5 (Cα), 61.3 (C-6), 67.1 (Fmoc-
CH2), 67.6, 70.1, 72.6, 72.7 (C-2,C-3,C-4,C-5), 91.9 (C-1), 119.9, 125.0, 125.1, 
127.0, 127.7, 141.2, 143.7, 143.7 (Ar-C), 155.5, 169.0, 169.0, 169.3, 169.3, 
170.0, 170.4 (C=O). 
Fmoc-L-Asn(βGlcAc4)-OH (11β), yield 95%. Rf = 0.19 (AcOEt/Hexane, 2:1, 
UV and vanilline). 1H NMR (400 MHz, 
CDCl3) δ = 2.00, 2.02 (2 s, 12H, 4×OAc), 
2.85 (system ABMX, JAB = 16.4 Hz, JAM 
= 4.4 Hz, JBM = 4.0 Hz, 2H, Asn-β-CH2), 
3.74 (pt, J = 4.8 Hz, 1H, H-5), 4.05 (d, J = 12.4 Hz, 1H, H-6), 4.19 (t, J = 7.2 
Hz, 1H, Fmoc-CH), 4.27 (dd, J = 12.8 Hz, J = 4.4 Hz, 1H, H-6’), 4.31-4.40 (m, 
2H, Fmoc-CH2), 4.59-4.61 (m, 1H, Asn-α-CH), 4.94 (t, J = 9.6 Hz, 1H, H-2), 
5.07 (t, J = 10 Hz, 1H, H-4), 5.27-5.35 (m, 2H, H-1 and H-3), 5.59 (broad s, 
1H, COOH), 6.25 (d, J = 8.0 Hz, 1H, Asn-α-NH), 7.06 (d, J = 9.2 Hz, 1H, NH-
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1), 7.28 (app-t, 2H, Fmoc-Ar), 7.37 (app-t, 2H, Fmoc-Ar), 7.57 (d, J = 7.2 Hz, 
2H, Fmoc-Ar), 7.73 (d, J = 7.2 Hz, 2H, Fmoc-Ar) ppm. 
8.3 Solid Phase Peptide Synthesis 
8.3.1 General procedure for batch SPPS on the manual PLS 4x4 
synthesizer 
Peptides are synthesized on a manual batch synthesizer (PLS 4×4, Advanced 
ChemTech) using a Teflon reactor (20 mL), following the Fmoc/tBu SPPS 
procedure. The resin is placed in the 20 mL Teflon reactor, equipped with a 
filter. Mixing is provided by vortex, while filtration is performed connecting 
the reactor to a vacuum pump. The resin is swelled for 40 min with DMF (1 
mL/100 mg of resin) before use. Each amino-acid cycle is characterized by the 
following four steps:  
Fmoc-deprotection: Resin is washed twice (1 × 5 min + 1 × 15 min) with 20% 
piperidine in DMF (1 mL/100 mg of resin). 
Washings: DMF (3 × 5 min), 
Coupling reaction: Fmoc protected amino acids (2.5 equiv) in DMF (1 
mL/100 mg resin), TBTU/HOBt/NMM (2.5 equiv, 2.5 equiv,:3.5 equiv) as 
coupling system for 45 min. 
Washings: DMF (3 × 5 min) and DCM (2 × 5 min). 
Deprotection of the second residue should be performed by a fast protocol to 
avoid DKP formation (3 × 5 min). For the coupling step a solution of the 
Fmoc-amino acid (4 equiv), TBTU (4 equiv), HOBt (4 equiv), and NMM (8 
equiv) in DMF (1 mL × 100 mg resin) is added to the resin. After DCM 
washings each coupling reaction is checked by a Kaiser test. After the last 
Fmoc-removal the resin is washed with DCM and dried under vacuum. 
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8.3.2 General procedure for in batch SPPS on an automatic peptide 
synthesizer 
All the reactions are performed in a Prelude™ parallel peptide synthesizer, in 
sealed reaction vessel under N2, where mixing and filtration is provided by a 
N2 flow. The resin is then swollen for 40 min. Each amino-acid cycle is 
characterised by the following four steps: 
• Fmoc-deprotection (1×5 min + 1×15 min), 
• Washings with DMF (5×2 min), 
• Coupling (2 x 20 min), 
• Washings with DMF (3×2 min). 
For the coupling reaction a 0.5 M solution of the Fmoc-protected amino acid 
and HOBt in DMF (4 equiv), 0.5 M solution of TBTU in DMF (4 equiv), and 
4 M solution of NMM in DMF (8 equiv) are used. DMF is eventually added to 
reach the good swelling volume of the resin (1 mL×100 mg). After removal of 
the last Fmoc-residue, the resin is washed with DCM and dried under N2 flow 
for 30 min. 
8.3.3 General procedure for Microwave-assisted SPPS 
The microwave-assisted solid phase peptide synthesis is performed on a 
LibertyTM Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC), 
an additional module of DiscoverTM (CEM Corporation, Matthews, NC) that 
combines microwave energy at 2450 MHz to SPPS following the Fmoc/tBu 
strategy. 
Each deprotection and coupling reaction is performed using microwave energy 
and N2 bubbling. Microwave cycle is characterized by two deprotection steps, 
the first one for 30 seconds, the second one for 180 seconds. All coupling 
reactions are performed for 300 seconds (Table  8.3.3). 
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Table  8.3.3 Microwave cycles for automatic MW-SPPS. 
Step Temp. (°C) MW Power (W) Time (sec) 
1st deprotection 70-75 25 30 
2nd deprotection 70-75 25 180 
coupling 70-75 25 300 
 
Peptides are synthesized on pre-loaded Wang Resin, using a scale of 0.1 or 
0.25 mmol. Deprotections are performed with 20% piperidine in DMF solution. 
All coupling reactions are performed with 2.5 equiv of 0.25 M solution of 
TBTU in DMF, 2.5 equiv of 0.1 M solution of amino acids in DMF and 3.5 
equiv of 0.7 M solution of DIPEA in NMP solution. Washing steps are 
performed with DMF and DCM. A complete amino acid coupling cycle is 
completed in 30 min. 
8.3.4 General procedure for cleavage  
Peptides and glycopeptides are cleaved from the resin using as cleavage 
mixture TFA/ethanedithiole/thioanisole/H2O/phenol (82.5:5:2.5:5:5) (reagent 
K). The peptide-resins are treated for 2.5 h with reagent K (1 mL × 100 mg of 
resin) at r.t.. The resin is filtered off and the solution is concentrated flushing 
with N2. The peptide is precipitated from cold Et2O or isoprophylethere as 
indicated for each reaction, centrifuged and lyophilized.  
8.3.5 General procedure for glycopeptide deacetylation 
Deacetylation of the sugar linked to the peptide is accomplished by adding 0.1 
M MeONa in MeOH to a solution of the raw material in dry MeOH (12 ml) 
until pH 12. After 1 h under stirring the reaction is quenched by adding dry 
CO2 to neutrality, the solvent is evaporated under vacuum and the residue 
lyophilized. 
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8.3.6 General procedure for pre-purification by solid-phase 
extraction (SPE) 
SPE is performed on RP-C18 LiChroprep columns. Main steps are reported 
here: Column washings with MeOH (3 column volumes) and CH3CN (3 
column volumes); column conditioning with H2O (3 column volumes); 
dissolving the peptide in H2O (1 column volume), checking the pH that should 
be neutral. Peptides are absorbed on silica by passing their solution for 3 times; 
eluting with H2O (3 column volumes) and after with 5%, 10%, 15%, 20% 
H2O/CH3CN (column volume for each concentration), and 100% CH3CN. 
Fractions are checked by analytical UPLC-ESIMS, and then lyophilized. 
 
Purification: All Peptides are further purified by semipreparative RP-HPLC 
using methods and solvent system reported in tables. Fractions are checked by 
UPLC-ESIMS to homogeneous ones 
8.3.7 Synthesis of CSF114(α-Glc) (Iα) and CSF114(β-Glc) (Iβ) 
Glycopeptides Iα and Iβ were synthesized on an automatic Prelude™ peptide 
synthesized, as described in the general procedure, starting from Fmoc-
Lys(Boc)-Wang resin (100 mg, 0.55 mmol/g). Fmoc-L-Asn(α-GlcAc4)-OH 
(11α) and Fmoc-LAsn(β-GlcAc4)-OH (11β) (1.5 equiv) were manually 
coupled using HOBt (1.5 equiv), TBTU (1.5 equiv) and NMM (3 equiv) in 
DMF for 1 h. Glycopeptides were cleaved from the resin and side chains were 
deprotected as described in the general procedure. Deprotection of the 
hydroxyl functions of sugars was performed as described in the general 
procedure and the glycopeptides were pre-purified by SPE and further purified 
by semipreparative RP-HPLC. Characterization of the peptides was performed 
using analytical HPLC and ESI-MS spectrometry. The analytical data are 
reported in Table  1.2.2. 
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8.3.8 Synthesis of Biotin-CSF114(Glc) (II)  and Biotin-CSF114 (II’) 
Biotinylated peptides II and II’ were synthesized on an automatic Prelude™ 
peptide synthesizer, as described in the general procedure, starting from Fmoc-
Lys-Wang resin (100 mg, 0.55 mmol/g). Fmoc-L-Asn(GlcAc4)-OH (11) (1.5 
equiv) was coupled in a manual batch synthesizer using HOBt (1.5 equiv), 
TBTU (1.5 equiv), and NMM (3 equiv) in DMF for 1 h. Peptide sequences 
were then completed in the automatic peptide synthesizer. N-biotinyl-6-
aminohexanoic acid was manually introduced at the N-terminus of the resin-
bound peptides using HOBt/TBTU (2.5 equiv) as activators for 1 h.  
Peptide cleavage from the resin and deprotection of the amino-acid side chains 
were carried out using reagent K. The resin was stirred for 3 h at room 
temperature. The resin was washed with TFA and the filtrate partially 
evaporated. Each crude product was then precipitated with diethyl ether, 
collected by centrifugation, dissolved in H2O and lyophilized. Deacetylation of 
the sugar moiety of peptide II was performed using 0.1 M MeONa in MeOH 
until pH = 12 added to a solution of the lyophilized peptide in dry MeOH (1 
mL/100 mg of resin). After 3 h the reaction was quenched by adding conc. 
HCl until pH = 7, the solvent was evaporated under vacuum and the residue 
lyophilized. Analytical data of the peptides are reported in Table  3.1. 
8.3.9 Synthesis of fluoresceinyl-CSF114(Glc)-PEG-Biotin (III) and 
fluoresceinyl-CSF114-PEG-Biotin (III’) 
Peptides III and III’ were synthesized on an automatic Prelude™ peptide 
synthesizer, as described in the general procedure, starting from biotin-PEG-
NovaTag™ resin (100 mg, 0.48 mmol/g). Fmoc-LAsn(GlcAc4)-OH (11) (1.5 
equiv) was manually coupled using HOBt (1.5 equiv), TBTU (1.5 equiv), and 
NMM (3 equiv) in DMF for 1 h. Peptide sequences were then completed in the 
automatic peptide synthesizer. 5(6)-Carboxyfluorescein was manually 
introduced at the N-terminus of the resin-bound biotinylated peptides using 
HOBt/DIPCDI (2.5 equiv) as activators for 2 h.  
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Peptides were cleaved and side chains were deprotected as described in the 
general procedure. Deprotection of the hydroxyl functions of the glycopeptide 
III was performed as described in the general procedure and the sequences 
were pre-purified by SPE and further purified by semipreparative RP-HPLC. 
Characterization of the peptides was performed using analytical HPLC and 
ESI-MS spectrometry. Analytical data of the peptides are reported in Table  4.1. 
8.3.10 Synthesis of ferrocenyl-labelled peptides and glycopeptides 
SPPS was performed by LibertyTM Microwave Peptide Synthesizer (CEM 
Corporation, Matthews, NC), an additional module of DiscoverTM (CEM 
Corporation, Matthews, NC) that combines microwave energy at 2450 MHz 
following the Fmoc/tBu SPPS strategy as described in the general procedure 
for microwave-assisted synthesis. CSF114 and CSF114(Glc) were prepared 
starting from Fmoc-Lys(Boc)-Wang resin (0.67 mmol/g). The glucosyl moiety 
of glycosylated peptides was introduced by the building-block Fmoc-L-
Asn(GlcOAc4)-OH (2.5 equiv) which was synthesized as previously reported 
in section  1.1. 
Ferrocenyl carboxylic acid (Fc-COOH) (2.0 equiv) was coupled with TBTU (2 
equiv), HOBt (2 equiv), and NMM (3 equiv) at the N-terminus of CSF114(Glc) 
and CSF114 sequences respectively for 1.5 h on a manual batch synthesizer 
(PLS 4×4, Advanced ChemTech) using Teflon reactors (10 mL) obtaining 
peptides IV and IV’. (Sp,S)-(+)–2-(tert-butoxycarbonylamino)–4-
(ferrocenylphenylthiophosphino)butanoic acid was coupled with TBTU (2 
equiv), HOBt (2 equiv), and NMM (3 equiv) at the N-terminus of the 
CSF114(Glc) and CSF114 sequences respectively for 1.5 h on a manual batch 
synthesizer obtaining peptides V and V’. 
Peptide cleavage from the resin and deprotection of the amino-acid side chains 
were carried out with 1 mL/100 mg resin of TFA/anisole/1,2-
ethanedithiol/phenol/H20 solution (96:1:1:1:1 v/v/v/v/v). Cleavage reaction 
mixture was maintained for 3 h at room temperature under stirring. The resin 
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was washed with TFA and the filtrate partially evaporated. Each crude product 
was precipitated with diethyl ether, collected by centrifugation, dissolved in 
H2O and lyophilized. Deacetylation of the sugar moiety linked to the peptide I-
IV and V was performed adding 0.1 M methanolic MeONa solution until pH = 
12 to a solution of the lyophilized peptide in dry MeOH (1 mL/100 mg resin). 
After 3 h the reaction was quenched by adding conc. HCl until pH = 7. The 
solvent was evaporated under vacuum and the residue lyophilized. 
All peptides were purified by semipreparative RP-HPLC and the purity of the 
peptides was checked using methods reported in Table  2.2.  
8.4 Immunoassays 
8.4.1 Solid-phase not competitive indirect ELISA (SP-ELISA) 
Serum was obtained for diagnostic purposes from patients and healthy blood 
donors who had given their informed consent, and stored at -20 ºC until use. 
Antibody responses were determined in SP-ELISA. Ninety-six wells activated 
polystyrene ELISA plates (NUNC Maxisorb SIGMA) were coated with 1 μg 
per 100 μl of peptides per well or glycopeptides in pure carbonate buffer 0.05 
M (pH 9.6) and incubated at 4 ºC overnight. After five washes with saline 
containing 0.05% Tween 20, non specific binding sites were blocked by fetal 
calf serum (FCS), 10% in saline Tween 20 (100 μl per well) at room 
temperature for 60 min. Sera diluted from 1:100 to 1:100.000 were applied at 4 
ºC overnight in saline/Tween 20/10% FCS. After five washes, it was added 
100 μl of alkaline phosphatase conjugated anti-human IgM (diluted 1:200 in 
saline/Tween 20/FCS) or IgG (diluted 1:8000 in saline/ Tween 20/FCS) 
(Sigma) to each well. After 3 h at room temperature incubation and five 
washes, 100 μl of substrate solution consisting of 1 mg/ml p-nitrophenyl 
phosphate (Sigma) in 10% diethanolamine buffer was applied. After 30 min, 
the reaction was stopped with 1M NaOH (50 μl), and the absorbance was read 
in a multichannel ELISA reader (Tecan Sunrise) at 405 nm. ELISA plates, 
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coating conditions, reagent dilutions, buffers, and incubation times were tested 
in preliminary experiments.24 The antibody levels are expressed as absorbance 
in arbitrary units at 405 nm (sample dilution 1:100). 
8.4.2 Measurement of antibody affinity by competitive ELISA 
Antibody affinity was measured following the methods previously reported.92 
The semi-saturating sera dilution (1:600) was calculated from the preliminary 
titration curves (absorbance, 0.7). At this dilution, Abs were preincubated with 
increasing synthetic peptide antigen concentration (0; 7.68×10-11; 7.68×10-10; 
7.68×10-9; 7.68×10-8; 7.68×10-7; 7.68×10-6; 3.84×10-5) for 1 h at room 
temperature. Unblocked Abs were revealed by ELISA, and the antigenic probe 
concentration-absorbance relationship was presented graphically. 
8.4.3 Antibodies purification by affinity chromatography 
Cyanogen-bromide activated resin (CNBr-Sepharose) was placed in a solid 
phase extraction tube (Supelco, Milan, Italy) and the resin was washed with 12 
ml of ice cold HCl (1 mM). This washing step facilitated the removal of 
lactose, used for stabilisation of the resin using freeze-drying. The resin was 
hence washed with Milli-Q water (12 ml) and a coupling buffer composed of 
NaHCO3 (0.1 M) and NaCl (0.5 M) pH = 8.3 (1 ml). The glycopeptide, 
CSF114(Glc), 1 mg, was dissolved in 1 ml coupling buffer (NaHCO3, 0.1 M, 
NaCl 0.5 M, pH = 8.3). The glycopeptide solution was thereafter added to the 
column and shaken overnight at room temperature. The functionalised resin 
was hence transferred to a solid phase extraction column closed at one end 
with a frit. The resin was allowed to settle and was subsequently washed with 
the coupling buffer. Unreacted groups were blocked using a glycine solution 
(0.2 M, pH = 8.0). In order to remove the washing solution, the functionalised 
resin was washed with the alkaline coupling buffer (10 ml), followed by 
washing with an acetate buffer (0.1 M, pH 4.3, 0.5 M NaCl) (10 ml). 
                                                     
92 Rath, S.; Stanley, C. M.; Steward, M. W. J Immunol Methods, 1988, 106, 245–249. 
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The serum from which the antibodies would be isolated was diluted 1:10 in 
PBS buffer and filtered through a 0.22 μm filter (Millex®-GS). Thereafter, the 
serum was loaded on the functionalised affinity column. The diluted serum 
was recirculated three times on the column. Anti-CSF114(Glc) antibodies 
were eluted by washing with: (a) 10 ml coupling buffer (pH = 8.3), (b) 10 ml 
PBS (pH = 7.0). Finally, the antibodies bound to the antigen (peptide) 
anchored to the resin, were eluted using a 0.2 M glycine solution (pH = 2.6). 
Washing and elution solutions were collected in Eppendorf tubes. Immediately 
after elution, fractions containing glycine buffer were immediately neutralised 
with 0.5 M NaHCO3 buffer. In order to determine the immunoreactivity the 
fractions were characterised using UV spectroscopy and Enzyme-linked 
immunosorbent assay (ELISA). 
8.4.4 BIAcore measurements procedure 
Direct amino coupling was carried out by directly linking the peptide antigens 
to the CM5 dextran coated chip. The immobilisation was achieved by firstly 
activating the sensor surface with N-hydroxysuccinimide (50 mM) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (200 mM) in water. 1 mM 
solution of peptide CSF114 was flowed through FC1 and a solution 1 mM of 
peptide CSF114(Glc) was flowed in the FC2 using 12 minutes interaction time 
with the sensor surface at a flow rate of 10 μl/min. Remaining activated sites 
were blocked using ethanolamine. 
Biotin/streptavidin coupling was performed by sensor chip activation using a 
solution of N-hydroxysuccinimide (50 mM) and N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide (200 mM) in water. Thereafter, streptavidin (100 μg/ml) 
in acetate buffer (10 mM, pH = 5.0) was passed over the chip for 10 minutes at 
a flow rate of 10 μl/min. Finally, a solution of ethanolamine-HCl (1 M, pH = 
8.5) was used to block any remaining activated sites. The peptide antigens, 
biotin-CSF114, as negative control and biotin-CSF114(Glc) were dissolved in 
Milli-Q water to a concentration of 1 mM and were hence diluted in HBS-EP 
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buffer to obtain final peptide concentration of 1 μM. Flow cell 3 (FC3) was 
saturated with biotin-CSF114 and flow cell 4 (FC4) was saturated with biotin-
CSF114(Glc) using 12 minutes interaction time with the sensor surface at a 
flow rate of 10 μl/min. 
Specific anti-CSF114(Glc) antibodies and serums were injected and flowed at 
30 μl/min in the designed flow cells for 120 sec. Anti-human IgG substrate 
was injected at dilution 1:100 for 120 sec at flow rate 30 μl/min. Regeneration 
solution was injected at 30 μl/min for 30 sec. 
8.5 Ferrocenyl electrochemical studies 
In a cyclic voltammetry (CV) experiment, the potentiostat applied a potential 
ramp to the working electrode to gradually change the potential and then 
reversed the scan, returning to the initial potential at a constant scan rate. The 
electrochemical instrumentation includes an EG&G 283 potentiostat connected 
to a PC and the collected data were analyzed using a Princeton Applied 
Research Software, Power Suite. A special electrochemical cell was used to 
handle only few microliters. The auxiliary electrode is a platinum wire and the 
reference is an Ag|AgCl electrode separated from the solution by a vycor tip. 
The active working electrode is a 1.6 mm diameter gold electrode (BAS) 
protected by 11-mercaptoundecanoic acid SAM for the ferrocenyl 
glycopeptide IV. In the case of V and V’, a mixture of 11-mercaptoundecanoic 
acid and decanethiol was used after immobilization of the ferrocenyl 
glycopeptides.  
The electrochemical measurements have been realized in a 0.05% Tween 20 
solution containing LiClO4 0.1M and potassium ferrocyanide (K4Fe(CN)6, 
Aldrich), 9 × 10-4 M at room temperature. The concentration of Fc-
CSF114(Glc) is 1.77 × 10-4 M. Specific autoantibodies were diluted at 1:1000. 
All solutions were deoxygenated prior to experiments 
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8.6 Optical Tweezers procedures 
8.6.1 Preparation of functionalized microscopic beads 
Both antigens and antibodies were coated to different functionalized 
polystyrene (latex) microparticles. 
Specific anti-CSF114(Glc) antibodies, purified as described in section  8.4.3, 
were attached to goat anti-human IgG (H&L) polystyrene latex microparticles 
(ø 3,0-3,9 μm, KISKER) by mixing in a vortex for 2 h. To remove unbounded 
antibodies the bead suspension was allowed to sediment for 1 hour on ice. 
Subsequently the supernatant was decanted and the pellet gently resuspended 
in D-PBS buffer supplemented with 0.5 mg/ml BSA and subsequently 
centrifuged. This procedure was repeated three times. Finally beads were 
suspended in 2 ml D-PBS buffer. 
A solution containing 50 μg of fluorescinyl biotinylated peptides III and III’ 
were attached to polystyrene (latex) beads functionalized with streptavidin 
(KISKER) by stirring for 30 min. Bead suspension was then centrifuged and 
washed with D-PBS buffer repeating for 3 times. The attachment of peptides 
to the beads was checked with fluorescence microscopy.  
8.6.2 Optical Tweezers measurements 
Interaction forces between the antigen CSF114(Glc) and specific IgG 
antibodies were measured with a double-beam counter-propagating optical 
tweezers apparatus. 93  Further customized set-up has been previously 
reported.64 Data acquisition were carried out by using custom-written LabView 
algorithms. The assay was carried out at room temperature in D-PBS buffer 
and 0.5 mg/ml BSA to block non-specific interactions. Microscopic beads 
were diluted. 
                                                     
93 (a) Kellermayer, M.S.Z., S.B. Smith, H.L. Granzier, and C. Bustamante, Science, 
1997, 276(5315), 1112-6. (b) Kellermayer, M.S., S.B. Smith, C. Bustamante, and H.L. 
Granzier, Biophys J, 2001, 80(2), 852-63. (c) Smith, S.B., Y. Cui, and C. Bustamante, 
Science, 1996, 271(5250), 795-9. 
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9. Experimental Part B 
9.1 Materials and methods 
The water used was obtained from demineralized water by distilling it once 
and then distilling the water so obtained from alkaline permanganate. Merck 
suprapur® KCl was baked at 500 ºC before use to remove any organic 
impurities. Dioleoylphosphatidylcholine (DOPC) was obtained from Lipid 
Products (South Nutfield, Surrey, England), while 
diphytanoylphosphatidylcholine (DphyPC), PG (L-α-phosphatidyl-DL-
glycerol), PC (egg yolk L-α-phosphatidylcholine), PS (phosphatidylserine) and 
2,3,di-Ophytanyl-sn-glycerol-1-tetraethylene-glycol-D,L-α lipoic acid ester 
lipid (DPTL) were obtained from Avanti Polar Lipids (Alabaster, AL). DOPC 
and DphyPC solutions were prepared by diluting a proper amount of stock 
solutions of these phospholipids with pentane. Solution of 0.2 mg/ml DPTL in 
ethanol was prepared from a 2 mg/ml solution of DPTL in ethanol. Stock 
solutions of these products were stored at -18 ºC. Stock solutions of peptides 
were prepared 5x10-3 M in methanol and were stored at +4 ºC. The other 
chemicals and solvents were commercially available and used as received. 
A Pyrex® glass sheltered beaker of 100 ml is used as electrochemical cell. 
Electrodes, as well as the bubbling scrubber used for induce gas 
deoxygenation, are supported in five holes in the cell tip. The whole cell is 
enclosed in a water-jacketed box thermostatically controlled at 25.5 ± 0.1°C. 
Moreover, the cell is put on a magnetic stirrer enabling to stir the solution. All 
the equipment is placed in a Faraday cage to decrease the background noise 
and supported by an antivibrating desk, to reduce vibrations interfering 
measures at low frequencies (Figure  9.1). 
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Figure  9.1. The scheme shows the equipment: 1, working electrode; 2, 
scrubber with auxiliary electrode; 3, reference electrode; 4, magnetic bar; 5, 
magnetic stirrer; 6, antivibrating desk; 7, air cushion; 8, water-jacketed box 
thermostatically controlled. 
All measurements were performed using a three-electrodes potentiostatic 
system, consisting of a Ag/AgCl (0.1M) as reference electrode, platinum wire 
wrapped around the scrubber as auxiliary electrode, and a home-made hanging 
mercury drop electrode (HMDE) as working electrode94. It allows accurate 
changes in drop area of as little as 0.04 mm2. Use was made of a home-made 
glass capillary (Metrohm, n°6.1209.010) with a finely tapered tip, about 1 mm 
in outer diameter. Capillary was silanized as described in the following section. 
Periodically, calibration and a test for reproducibility of the HMDE are 
performed. The HMDE and the support were moved vertically and 
horizontally, respectively, by means of two oleodynamic systems that ensured 
the complete absence of vibrations. Using the oleodynamic system, mercury 
drop of the HMDE could be completely immersed into the electrolyte solution 
passing thought the interface solution.  
All glassware is treated with chromic acid solution, useful to remove organic 
deposits; sometimes the cleaning procedure is performed under heating, to 
remove lipidic residues. Then, so-treated glassware is washed with abundant 
                                                     
94 Moncelli, M.R.; Becucci, L,  Journal of Electroanalytical Chemistry, 1997, 433, 91-
96. 
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bi-distillate water and, finally, is covered with a tinfoil and dried at 150°C in 
the oven. 
AC voltammetry and impedance spectroscopy measurements were carried out 
with an Autolab instrument (EchoChemie) supplied with FRA2 module for 
impedance measurements, SCAN-GEN scan generator and GPES3 software. 
Potentials were measured versus one Ag/AgCl (0.1 M KCl) reference 
electrode. The applied potential was then measured over a potential range, 
while continuously monitoring the curve of the differential capacity, C, vs. the 
applied potential, E. 
9.1.1 Capillary silanization 
The silanization procedure is described as follow: the capillary was put in a 
NaOH 1M alcoholic solution for 12h, to remove the old silanization. After that, 
it was washed with a HCl 0.1M solution, bi-distillate water and finally ethanol. 
Then, it was dried in oven at 140-150°C for 2h and successively cooled to 
room temperature. When the previous silanization is completely removed, it is 
possible to make a new one, putting the head of capillaries in 2-3 cm of a 5% 
dimethylchlorosilane (DMS) in toluene solution. In this condition, the 
silanizing solution will climb up inside the wall of the capillary. This step 
require a great attention to keep out water from DMS solution, otherwise there 
will be an occlusion of capillaries due to the polimerization of silane. The 
excess of DMS is washed with abundant toluene, dry in oven at 140-150°C for 
2 h and cooled to room temperature. 
9.1.2 Electrochemical Analysis 
The stand-by potential to conserve membrane integrity was -0.4V. 
Electrochemical analyses were performed using the next parameters  
AC Voltammetry scans were recorder for potentials between -0.2V and -1.2V 
using 0.00705V as step potential. 
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Cyclic Voltammetry scans were performed from -0.9V as fist vertex potential 
to -0.3V as second vertex potential with a scan rate of 0.5 V/s and a step 
potential of 0.00244V.  
Electrochemical impedance spectroscopy (EIS) spectra were recorded for 
frequencies between 0.01/0.1 Hz and 105 Hz starting from -0.3 V potential to  
-1 V.  
9.2 Peptide and glycopeptide synthesis 
Glycopeptides CSF114(Glc) I and Scramble CSF114(Glc) VI were 
synthesized on an automatic Prelude synthesizer, as described in the general 
procedure, starting from Fmoc-Lys-Wang resin (100 mg, 0.6 mmol/g) and 
Fmoc-Pro-Wang resin respectively. Fmoc-L-Asn(GlcAc4)-OH (1.5 equiv) was 
manually coupled using HOBt (1.5 equiv), TBTU (1.5 equiv). and NMM (3 
equiv) in DMF for 1.5 h in a manual PLS 4x4 synthesizer.  
Peptides CSF114 (I’), Scramble CSF114 (VI’), MBH36 (VII), and TripZip 
(VIII) were synthesized in an automatic Prelude synthesizer, as described in 
the general procedure, starting from the corresponding Fmoc-Xaa(Pg)-Wang 
resin (100 mg, 0.6 mmol/g). 
Peptides and glycopeptides were cleaved and side chains were deprotected as 
described in the general procedure. Deprotection of the hydroxyl functions of 
glucose was performed as described in the general procedure and the peptides 
were pre-purified by SPE and further purified by semi-preparative HPLC. 
Characterization of the peptides was performed using analytical HPLC and 
ESI-MS spectrometry. Analytical data of all peptides are reported in Table  9.2. 
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Table  9.2. Peptides in biomimetic membrane 
peptide HPLC (Rt,min) 
ESI-MS [M+2H]2+ 
Calc (found) 
CSF114(Glc) (I) 14.8a 1303.6 (1303.8) 
CSF114 (I’) 14.1a 1223.3 (1223.9) 
Scramble CSF114(Glc) (VI) 17.0b 1303.6 (1304.1) 
Scramble CSF114 (VI’) 15.1c 1223.3 (1223.9) 
MBH36 (VII) 15.4d 839.4 (839.9) 
TripZip (VIII) 7.4e 804.8 (805.4) 
aAnalytical HPLC gradients at 1 mL min-1, 20-60% B in 20 min, b25-35% B in 25 min, c 
25-40% B in 30 min, d 05-40% B in 20 min, e 30-70% B in 20 min; solvent system A: 
0.1% TFA in H2O, B: 0.1% TFA in CH3CN; 
9.3 Bilayer preparation 
The preparation of a tethered bilayer lipid membrane (tBLM) consists in two 
steps:  
1) preparation of a self-assembled monolayer of a thiolipid, 
2) formation of a phospholipids monolayer on top of the thiolipid 
monolayer. 
DPTL was self-assembled on the HMDE by keeping the mercury drop 
immersed in the small vessel containing the spacer solution (0.2 mg/ml) for 20 
min (Figure  9.3.1) A solution of DOPC or DphyPC in pentane was spread on 
the surface of the 0.1 M KCl aqueous solution contained in the electrochemical 
cell. The amount of phospholipids spread corresponds to five or six 
monolayers at the air/solution interphase.  
 
Figure  9.3.1. DPTL monolayer formation steps. 
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Using the oleodynamic system, the spacer-coated HMDE was then extracted 
from the vessel, washed with the organic solvent to remove the excess of 
adsorbed spacer, and kept in an Ar atmosphere for the time necessary to allow 
the solvent to evaporate. Immediately afterwards, the electrochemical cell 
containing the aqueous solution, on whose surface the phospholipid had been 
previously spread, was placed just below the HMDE and the electrode was 
then immersed into the electrolyte solution across the phopholipid film (figure 
 9.3.2). 
  
Figure  9.3.2. Second step: bilayer formation immersing DPTL-coated Hg 
drop through a DphyPC film spreaded at air-water interface. 
The integrity of self-assembled bilayer was characterized using AC 
voltammetry and electrochemical impedance spectroscopy (EIS) techniques. 
Peptides and glycopeptides were directly added to the electrolyte solution. 
9.4 Liposomes-peptide incubation 
Peptides-liposomes interactions were assayed by measuring fluorescence. A 
film of lipid was prepared on the inside wall of a round-bottom flask by 
evaporation of CHCl3 solutions containing the proper amount of PC/PG (2:1). 
The suspension was freeze–thawed in liquid nitrogen for nine cycles and 
extruded 30 times through polycarbonate filters (two stacked 0.2-μm pore size 
filters) using an Avanti Mini-Extruder (Avanti Polar Lipids inc., Alabaster, 
AL). Vesicles in suspensions containing 100 μM lipids were incubated with 
various concentrations of the peptide CSF114 (0.6–20 μM), or the fixed 
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concentration of CSF114 (1 μM) was incubated with vesicles (4-300 μM). The 
fluorescence of the Trp residue was assessed with a spectrofluorometer 
(Perkin-Elmer LS55) at an excitation wavelength of 280 nm and an emission 
wavelength between 320 and 420 nm. The experiments were conducted at 
25°C.  
9.4.1 Anisotropy measurements 
Anisotropy of vesicles and vesicles containing peptide CSF114 was calculated 
using a polarization mode. The fluorescence of the Trp residue was assessed 
with a spectrofluorometer (Perkin-Elmer LS55) at an excitation wavelength of 
280 nm and an emission wavelength 350 nm. G-factor of the instrument was 
previously calculated (1,566332). Anisotropy of a solution containing 10 μM 
of CSF114 was calculated in absence and in presence of liposomes (300 μM) 
. 
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10. Description of the techniques 
10.1 Surface plasmon resonance 
The physical principles of SPR are complex, but fortunately, an adequate 
working knowledge of the technique does not require a detailed theoretical 
understanding. It suffices to know that SPR-based instruments use an optical 
method to measure the refractive index near (within ~300 nm) a sensor surface. 
In the BIAcore this surface forms the floor of a small flow cell, through which 
an aqueous solution (henceforth called the running buffer) passes under 
continuous flow (1-100 μl min-1). In order to detect an interaction one 
molecule (the ligand) is immobilised onto the sensor surface.  
 
Figure  10.1 Schematic diagram of Surface Plasmon Resonance. 
Its binding partner (the analyte) is injected in aqueous solution (sample buffer) 
through the flow cell, also under continuous flow. As the analyte binds to the 
ligand, the accumulation of protein on the surface results in an increase in the 
refractive index. This change in refractive index is measured in real time, and 
the result plotted as response or resonance units (RUs) versus time (a 
sensorgram). Importantly, a response (background response) will also be 
generated if there is a difference in the refractive indices of the running and 
sample buffers. This background response must be subtracted from the 
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sensorgram to obtain the actual binding response. The background response is 
recorded by injecting the analyte through a control or reference flow cell, 
which has no ligand or an irrelevant ligand immobilized to the sensor surface. 
By effectively adding a third dimension to the surface, much higher levels of 
ligand immobilisation are possible. 
10.2 Optical Tweezers 
Optical Tweezers use light to manipulate microscopic objects as small as a 
single atom. The radiation pressure from a focused laser beam is able to trap 
small particles. The optical forces exerted on a particle originate from the 
momentum change of the photons impinging on the particle. These forces have 
traditionally been decomposed into two components: gradient force and 
scattering force.95  The scattering force acts, for a symmetric beam, in the 
propagation direction of the beam. The gradient force, in case of a particle 
with a refractive index greater than that of the surrounding medium, is directed 
towards the region of highest light intensity. 
For a spherical particle with refractive index np greater than that of the 
surrounding medium (nm), the action of two parallel beams (K and L) with 
different intensities (K>L), both of which becoming refracted and therefore 
giving rise to a force (F), will result in the generation of an asymmetric net 
force (Figure  10.2.1A). As a result, the particle is propelled toward regions of 
greater light intensity. In the case of converging light rays (M and N), as near a 
focal point of a microscopy objective lens (Figure  10.2.1B), the net force 
points in a direction parallel with the optical axis. Depending on the position 
of the bead relative to the focal point, however, the net force may point down 
or up (Figure  10.2.1B) the optical axis. In the balance of gradient and 
scattering forces the particle may become stably trapped. Stable trapping will 
occur if the potential well defined by the optical trap is deep enough compared 
                                                     
95 Ashkin, A.; Dziedzic, J.M.; Bjorkholm, J.E.; Chu, S. Optics Lett, 1986, 11(5), 288-
290. 
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with the thermal energy of the particle. The geometry depicted in Figure 
 10.2.1B forms the basis of the most commonly used single-beam optical 
tweezers.  
 
A B
 
Figure  10.2.1. Schematics of the geometrical optics description of gradient 
force for a particle with an index of refraction greater than that of the medium. 
(A) For a lateral intensity gradient, the resulting force, due to the refraction of 
the light at the interface, has a component toward the greater intensity. (B) In 
a focused laser beam, the axial force propels the particle toward the focal 
point. 
The potential well defined by the optical trap can be thought of as a spatially-
defined virtual spring with a stiffness (spring constant) of ĸ. The force acting 
on the particle can then be written as 
    
r
F = −κΔrx , 
where Δx is the displacement of the particle from the trap center. Thus, if we 
know the trap stiffness, measuring bead position allows the determination of 
the force acting on the bead. With a ~10 nm position measurement accuracy of 
microscope image processing techniques and ~0.1 pN/nm stiffness of common 
optical tweezers, ~ 1 pN force resolution may be reached. By using more 
sophisticated position sensing methods, the force resolution may be increased 
further. Bead position may be measured with high precision by using quadrant 
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photodetectors.96 Another simple method is projecting the position – in the 
condensor back focal plane – of the trapping laser, after it has left the optical 
trap, onto a position-sensing photodiode. 97  These approaches yield sub-
piconewton force resolution. Considering that the changes in the laser-beam 
trajectory evoked by interaction with the trapped bead reflect the changes in 
light momentum, by measuring the position of the laser beam after it has left 
the trap allows, in principle for a direct measurement of force (Figure 
 10.2.2).98 
 
 
Figure  10.2.2. Measuring the force on a trapped bead. When a bead is moved 
from the trap centre due to an external force, the trapping laser beam is 
deflected. If the input aperture of the objective is underfilled in a dual-beam 
optical tweezers instrument, this deflection can be directly measured using a 
position-sensitive photodiode detector. 
In this arrangement all the photons entering the trap must be collected after 
they have left the trap and deviated from the optical axis, the objective lens 
back aperture needs to be underfilled with the laser beam. On the other hand, a 
major advantage of this arrangement is that the often tedious trap stiffness 
procedures can be avoided. In this thesis such a dual-beam counter-
                                                     
96 Finer, J.; Simmons, R.; Spudich, J. Nature, 1994, 368, 113-119. 
97 Ghislain, L.P.; Switz, N.A.; Webb, W.W. Rev Int Instrum, 1994, 65(9), 2762-2768. 
98 (a) Smith, S.B.; Cui, Y.; Bustamante, C. Methods Enzymol, 2003, 361, 134-62. (b) 
Smith, S.B.; Cui, Y.; Bustamante, C. Science, 1996, 271(5250), 795-799. 
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propagating optical tweezers instrument that functions as a light-momentum 
sensor was used.  
10.3 AC Voltammetry 
Alternating current (AC) voltammetry is a frequency-domain technique that 
involves the superimposition of a small-amplitude AC voltage on a linear ramp 
(Figure  10.3). The alternating potential, usually, has a frequency of 50-100 Hz 
and an amplitude of 10-20 mV. The AC signal thus causes a perturbation in 
the surface concentration, around the concentration maintained by the DC 
potential ramp. The resulting AC current is displayed versus the potential. The 
detection of AC component allows to separate the contributions of the faradaic 
and charging currents. The former is phase shifted 45° relative to the applied 
sinusoidal potential, while the background component is 90° out of phase. The 
current is recorded as a function of time. Since the potential also varies with 
time, the results are usually reported as the potential dependence of current, or 
plots of I vs. E, hence the name voltammetry. 
 
Figure  10.3. Potential-time waveform used in AC voltammetry. 
DESCRIPTION OF THE TECHNIQUES 
 124
10.4 Cyclic Voltammetry 
Cyclic voltammetry is the most widely used technique for acquiring qualitative 
information about electrochemical reactions. The efficacy of cyclic 
voltammetry results from its ability to rapidly provide considerable 
information on the thermodynamics of redox processes, on kinetics of 
heterogeneous electron-transfer reactions, and on coupled chemical reactions 
or adsorption processes. Cyclic voltammetry consists of scanning linearly the 
potential of a stationary working electrode, starting from an initial potential Ei 
to a final potential Ef, using a triangular potential waveform (Figure 6.12). 
Depending on the information sought, single or multiple cycles can be used. 
During the potential sweep, the potentiostat measures the current resulting 
from the applied potential. 
 
Figure  10.4. Potential-time signal in cyclic voltammetry. 
The characteristic peaks in the cyclic voltammogram are caused by the 
formation of the diffusion layer near the electrode surface, generating different 
process (reversible, irreversible or quasi-reversible). 
The electron transfer reaction O + ne- → R can be considered with only О 
initially present in solution. Therefore the initial sweep direction must be 
negative. 
A faradaic current, If, depends on the kinetics and transport by diffusion of the 
electroactive species, is registered in the relevant zone of applied potential 
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where electrode reaction occurs. There is also a capacitive contribution: on 
sweeping the potential the double layer charge changes; this contribution 
increases with increasing sweep rate. The total current is: 
I = Ic + If = C dE/dt + If 
In absence of faradaic process, such as the case of lipidic monolayers on 
mercury, the current is purely capacitive; therefore: 
dt
dEC
dt
dQI ==
 
Because of dE/dt represents the scan velocity, it has obtained 
I=C·v 
As a consequence, cyclic voltammogram has a diagram reflecting trend of 
differential capacity. Moreover, based on Ohm’s Law V=i·R, it is possible to 
calculate the inclination of cyclic voltammogram, that is 1/R. 
10.5 Electrochemical impedance spectroscopy 
Electrochemical Impedance Spectroscopy (EIS) represents a powerful 
technique for the characterization of biological systems. Although, in recent 
years, EIS has found widespread applications in the field of characterization of 
materials, it results a suitable technique for the investigation of diffusion of 
ions across membranes. 
In a typical impedance spectral measurement, a small amplitude sinusoidal 
voltage is applied between two electrodes at successive frequencies and the 
current response is measured. A low amplitude sine wave (ΔEsinωt), of a 
particular frequency, is superimposed on the dc polarization voltage E0. This 
results in a current response of a sine wave ΔIsin(ωt+Ф) superimposed on the 
dc current I0. The current response is shifted with respect to the applied 
potential. 
The frequency-dependent impedance Z is usually described by complex 
numbers, whose real and imaginary parts are derived from the currents in 
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phase and 90° out of phase with the applied ac voltage, respectively. An 
impedance spectrum can often be fitted by an equivalent electrical circuit 
composed of resistors and capacitors. 
The relationship between the applied potential and the current flow is known 
as the impedance, which is analogous to the resistance-current-potential 
relationship of a dc circuit. The impedance (Z) has a magnitude (ΔE/Δi) and 
phase (φ) and is thus a vector quantity. 
If a sinusoidal potential is applied across a pure resistance of magnitude R, 
then the magnitude of the impedance Z = R and the phase φ = 0 for all 
frequencies. This is shown on a plot of the real and imaginary components as a 
point on the real axis overleaf. 
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Abbreviations 
Ab: antibody; 
Ac: Acetyl; 
Ag: Antigen; 
APC: Antigen presenting cell; 
BLM: bilayer lipid membrane;  
Bn: Benzyl; 
Boc: tert-butoxycarbonyl; 
CNS: Central Nervous System 
DCM: dichloromethane; 
DIPEA: diisopropylethylamine; 
DMF: N,Ndimethylformamide; 
DMS: dimethylchlorosilane; 
DOPC: dioleoyl phosphatidylcholine;  
DPhyPC: diPhytanyl phosphatidyl coline;  
DPTL: 2,3,di-O-phytanyl-sn-glycerol-tetraethyleneglycol-lipoic acid ester 
lipid;  
EIS: electrochemical impedance spectroscopy;  
ELISA: enzyme-linked immunosorbent assay; 
FCC: flash column chromathography; 
FCS: fetal calf serum; 
FIA: fluorescence immunoassay; 
Fmoc: 9-H-fluoren-9-ylmethoxycarbonyl; 
GBS: Guillian Barré syndrome; 
HMDE: hanging drop mercury electrode; 
HOBt: 1-hydroxybenzotriazole; 
HPLC: high performance liquid chromatography; 
Ig: immunoglobulin (IgE, IgG, etc.); 
MHC: major histocompatibility complex; 
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MOG: myelin oligodendrocyte glycoprotein; 
MRI: Magnetic Resonance Imaging; 
MS: Multiple Sclerosis; 
MW: microwaves; 
NBD’s: Normal Blood Donors: 
NMM: N-methyl morpholine; 
NMR: nuclear magnetic resonance; 
OT: Optical tweezers; 
PBS: phosphate buffered saline; 
PEG: polyethylene glycol;  
Pfp: pentafluorophenyl;  
Ph: phenyl; 
psBLM: polymer-supported bilayer lipid membranes; 
RA: Rheumatoid Arthritis; 
RIA: radioimmunoassay; 
SPE: solid phase extraction; 
SPPS: solid phase peptide synthesis; 
SPR: Surface plasmon resonace; 
ssBLM: solid supported bilayer lipid membranes;  
SSM: solid supported membrane; 
TBAT: Tetrabutylammonium Triphenyldifluorosilicate; 
tBLM: tethered bilayer lipid membranes;  
TBTU: 2 - (1H-benzotriazole-1-yl) - 1,1,3,3 - tetramethyluronium 
tetrafluoroborate; 
tBu: tert-butyl; 
TCR: T-cell receptor; 
TFA: trifluoroacetic acid; 
THF: tetrahydrofurane; 
TLC: Thin layer chromatography. 
TMS-N3: trimethylsilyl azide. 
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